[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2751
1. Henriksson R, Malmström A, Bergström P, Bergh G, Trojanowski T, Andreasson L, Blomquist E, Jonsborg S, Edekling T, Salander P, Brännström T, Bergenheim AT: High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol; 2006 Jul;78(3):321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.
  • Experimental and early clinical investigations have demonstrated encouraging results for estramustine in the treatment of malignant glioma.
  • The present study is an open randomized clinical trial comparing estramustine phosphate (Estracyt) in addition to radiotherapy with radiotherapy alone as first line treatment of astrocytoma grade III and IV.
  • Estramustine was given orally, 280 mg twice daily, as soon as the diagnosis was established, during and after the radiotherapy for a period of in total 3 months.
  • For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
  • In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy, however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Estramustine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1713-6 [2697186.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):360-6 [8832674.001]
  • [Cites] Br J Cancer. 1988 Sep;58(3):326-9 [3052561.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1394-400 [1873791.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Prostate. 1989;14(1):27-43 [2648345.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):693-6 [2369085.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):215-20 [15072470.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1111-7 [11181676.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):962-4 [1709687.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):358-61 [8431366.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):535-43 [10348282.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):142-8 [10389990.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1254-9 [10715295.001]
  • [Cites] J Neurooncol. 1994;22(2):111-26 [7745464.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):717-20 [7710934.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):87-91 [9516956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):555-7 [8005815.001]
  • [Cites] Clin Pharmacokinet. 1998 Feb;34(2):163-72 [9515186.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1415-7 [8137240.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):422-30; discussion 430-1 [8384327.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2079-84 [9748122.001]
  • [Cites] J Neurooncol. 1995;23(3):191-200 [7673981.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4974-9 [8069865.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurol. 1975 Jul 2;209(3):217-24 [51062.001]
  • (PMID = 16598426.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35LT29625A / Estramustine
  •  go-up   go-down


2. Omar AI, Mason WP: Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas. Core Evid; 2010 Jun 15;4:93-111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas.
  • INTRODUCTION: Malignant gliomas are a heterogeneous group of primary central nervous system neoplasms that represent less than 2% of all cancers yet carry a significant burden to society.
  • Temozolomide (TMZ) is a new second generation DNA alkylating agent that has become part of malignant astrocytoma management paradigms because of its proven efficacy, ease of administration, and favorable toxicity profile.
  • AIMS: To review the role of TMZ in the management of malignant astrocytomas (World Health Organization grades III and IV) including newly diagnosed (n) and recurrent (r) anaplastic astrocytomas (AA) and glioblastomas.
  • EVIDENCE REVIEW: A series of pivotal clinical trials have established a role for TMZ in the treatment of malignant astrocytomas.
  • Evidence for a role of TMZ in nAA is currently limited but research is ongoing in this area.
  • PLACE IN THERAPY: THERE IS EVIDENCE TO SUPPORT THE USE OF TMZ FOR THE FOLLOWING DISEASES IN THE ORDER OF MOST TO LEAST CONVINCING: nGBM, rAA, rGBM, and nAA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2000 May 16;132(10):769-79 [10819699.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2098-105 [15389472.001]
  • [Cites] Oncol Rep. 2000 Jul-Aug;7(4):899-904 [10854567.001]
  • [Cites] Cancer. 2003 May 1;97(9):2262-6 [12712481.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1598-604 [15117981.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2372-7 [15800329.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1004-11 [12671695.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1583-8 [15051755.001]
  • [Cites] J Oncol Pharm Pract. 2006 Jun;12(2):105-11 [16984749.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] Neurosurgery. 1998 Aug;43(2):398-9 [9696102.001]
  • [Cites] Neuro Oncol. 2002 Jan;4(1):39-43 [11772431.001]
  • [Cites] Cancer. 2004 May 15;100(10):2208-14 [15139066.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):139-50 [8901377.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • [Cites] J Neurosurg. 1993 May;78(5):767-75 [8468607.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):191-200 [15072467.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Trends Biochem Sci. 1995 Oct;20(10):421-6 [8533156.001]
  • [Cites] Health Technol Assess. 2001;5(13):1-73 [11359682.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):771-3 [17550757.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):764-72 [10048980.001]
  • [Cites] Anticancer Drugs. 2004 Jun;15(5):499-502 [15166625.001]
  • [Cites] Brain Pathol. 1995 Apr;5(2):145-51 [7670655.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):127-37 [11325440.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2236-41 [9038604.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jun;3(6):339-43; quiz following 343 [16757971.001]
  • [Cites] Cancer Treat Rev. 2006 Oct;32(6):483-6 [16730911.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):189-95 [15831237.001]
  • [Cites] Neuro Oncol. 1999 Apr;1(2):124-37 [11550308.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):163-9 [11285554.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1593-607 [17134364.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] N Engl J Med. 2007 Apr 12;356(15):1527-35 [17429084.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):4-5 [16314613.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Oncology (Williston Park). 1998 Apr;12(4):537-43, 547; discussion 547-8, 553 [9575527.001]
  • [Cites] Mol Cancer Ther. 2002 Nov;1(13):1229-36 [12479704.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Oncology. 2002;63(1):38-41 [12187069.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):380-6 [15667956.001]
  • [Cites] No Shinkei Geka. 1992 Apr;20(4):493-7 [1570077.001]
  • [Cites] Eur J Cancer. 1993;29A(7):940-2 [8499146.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Neuro Oncol. 1999 Jul;1(3):169-76 [11550311.001]
  • [Cites] Acta Oncol. 2004;43(6):579-84 [15370616.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):589-600 [9681071.001]
  • [Cites] J BUON. 2002 Jan-Mar;7(1):35-41 [17577258.001]
  • [Cites] Oncologist. 2006 Feb;11(2):165-80 [16476837.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):997-1007 [6349785.001]
  • [Cites] Br J Neurosurg. 2002 Aug;16(4):335-42 [12389885.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):942-9 [15870090.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Aug;294(2):664-71 [10900246.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2601-6 [17577040.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4675-86 [17214326.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] J Neurosurg. 1989 Jul;71(1):1-9 [2661738.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Acta Neurochir (Wien). 2003 Jan;145(1):5-10 [12545256.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Qual Life Res. 1996 Dec;5(6):555-67 [8993101.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):295-303 [17001519.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4412-7 [16983109.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] Biochemistry. 1994 Aug 9;33(31):9045-51 [8049205.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1712-6 [15073861.001]
  • [Cites] Am J Clin Oncol. 2002 Dec;25(6):606-11 [12478010.001]
  • [Cites] N Engl J Med. 1977 Mar 31;296(13):716-21 [402576.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):779-84 [10837964.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Anticancer Drugs. 1997 Jan;8(1):92-7 [9147618.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1038-44 [15305187.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):433-41 [8892469.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):38-43 [14769139.001]
  • [Cites] Neuroepidemiology. 2006;27(1):55-6 [16825795.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):248-51 [12865911.001]
  • [Cites] Curr Mol Med. 2003 Feb;3(1):73-84 [12558076.001]
  • [Cites] J Neurooncol. 1994;21(2):135-40 [7861189.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1383-8 [11870183.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14):1788-95 [10974627.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):203-8 [15015788.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Pharmacoeconomics. 2005;23(8):803-15 [16097842.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):85-9 [17031555.001]
  • [Cites] J Health Econ. 1988 Sep;7(3):289-90 [10291478.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3728-36 [15173079.001]
  • [Cites] J Neurosurg. 2001 Aug;95(2):190-8 [11780887.001]
  • [Cites] Int J Radiat Biol. 2002 Oct;78(10):931-6 [12465658.001]
  • (PMID = 20694068.001).
  • [ISSN] 1555-175X
  • [Journal-full-title] Core evidence
  • [ISO-abbreviation] Core Evid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2899776
  • [Keywords] NOTNLM ; anaplastic astrocytoma / evidence / glioblastoma / glioma / malignant astrocytoma / temozolomide
  •  go-up   go-down


3. Mennel HD, Lell B: Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors. Clin Neuropathol; 2005 Jan-Feb;24(1):13-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglioside (GD2) expression and intermediary filaments in astrocytic tumors.
  • The search of proliferation markers in astrocytic tumors that may serve as targets for therapeutic interventions, is in full progress.
  • Gangliosides are lipid-sugar compounds localized on the cell membrane that are thought to modify pertinent signals and, therefore, may influence a variety of functions in normal and pathologic conditions including those that act upon tumor growth.
  • Intracranial supratentorial astrocytic gliomas of the adult represent a tumor group, that may be divided into three grades of malignancy, the most anaplastic member being the glioblastoma.
  • Yet, the results were only partly congruent and the correlation to tumor grades rather loose.
  • Thus, the conclusion must be drawn that the correlation of ganglioside patterns to the proliferation of astrocytic tumors is as poor as that of GFAP or vimentin expression, respectively.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Gangliosides / metabolism. Intermediate Filaments / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696779.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Gangliosides; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin; 65988-71-8 / ganglioside, GD2
  •  go-up   go-down


Advertisement
4. Ward SJ, Karakoula K, Phipps KP, Harkness W, Hayward R, Thompson D, Jacques TS, Harding B, Darling JL, Thomas DG, Warr TJ: Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation. J Neurooncol; 2010 Jul;98(3):305-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation.
  • Little is known about the cytogenetic and molecular genetic events that lead to the formation of paediatric astrocytoma.
  • We have analysed 57 paediatric astrocytoma (WHO grades I-IV) using comparative genomic hybridisation in order to identify common regions of abnormality.
  • The presence of copy number alterations was significantly associated with increasing grade of malignancy, and gain of 12q and the presence of high-copy number amplification were associated with a poor outcome in patients with malignant astrocytoma (P = 0.0039 and 0.0085, respectively).
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Comparative Genomic Hybridization / methods. In Situ Hybridization, Fluorescence / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]
  • [Cites] Genes Chromosomes Cancer. 2001 May;31(1):15-22 [11284031.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jan;12(1):63-5 [7534113.001]
  • [Cites] J Neurooncol. 1987;4(3):293-308 [3559666.001]
  • [Cites] Childs Nerv Syst. 1998 Nov;14 (11):636-48 [9840364.001]
  • [Cites] Neurosurgery. 1992 Jan;30(1):58-62; discussion 62-3 [1738456.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):265-73 [9950497.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12 ):4085-90 [10632344.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Nov;71(1):40-9 [8275451.001]
  • [Cites] Genes Chromosomes Cancer. 2002 May;34(1):69-77 [11921284.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):117-22 [12241104.001]
  • [Cites] Pol J Pathol. 1998;49(4):267-71 [10323080.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):108-19 [8569172.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Cancer. 1993 Aug 15;72 (4):1404-13 [8339231.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):67-72 [10958944.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Nov;64(1):75-9 [1333880.001]
  • [Cites] Childs Nerv Syst. 2001 Jan;17(1-2):31-6 [11219620.001]
  • [Cites] Cancer Genet Cytogenet. 1992 May;60(1):67-73 [1591709.001]
  • [Cites] Cancer. 1980 Jun 1;45(11):2787-92 [7379009.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):171-6 [3392563.001]
  • [Cites] J Neurosurg. 1986 Dec;65(6):751-5 [3772472.001]
  • [Cites] Curr Opin Neurol. 1994 Dec;7(6):484-91 [7866579.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):173-7 [11836716.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Jun;81(2):125-34 [7621408.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8241-6 [8710854.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Acta Neurochir (Wien). 1982;62(3-4):219-32 [7102387.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Dec;11(4):205-15 [7533523.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Oct 1;91(1):13-27 [8908162.001]
  • [Cites] Cancer Res. 2009 Jul 15;69(14):5630-3 [19567670.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Aug;28(4):325-33 [12175345.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Nov;131(1):1-12 [11734311.001]
  • [Cites] Genes Chromosomes Cancer. 1997 May;19(1):6-13 [9135989.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2091-6 [17934519.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):431-9 [14655749.001]
  • [Cites] Cell. 1997 Mar 21;88(6):747-56 [9118218.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1218-22 [10735509.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Sep;97(2):125-34 [9283596.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 Sep;44(9):820-8 [7310422.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1324-30 [8118823.001]
  • [Cites] Brain Tumor Pathol. 2000;17(1):21-7 [10982006.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):544-58 [10850867.001]
  • [Cites] Brain Pathol. 2000 Apr;10 (2):249-59 [10764044.001]
  • [Cites] Pediatr Hematol Oncol. 1992 Jul-Sep;9(3):223-35 [1525001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):704-10 [11597812.001]
  • [Cites] Folia Biol (Praha). 2000;46(5):187-90 [11055797.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(1):17-26 [8154317.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(15):1955-64 [11000577.001]
  • [Cites] Mutat Res. 2005 Jun 3;573(1-2):70-82 [15829238.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Mar;59(1):12-9 [1313329.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):175-80 [3334992.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11172-8 [17145861.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Apr;15(4):199-205 [8703845.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12 ):2736-9 [8504413.001]
  • (PMID = 20052518.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Opstad KS, Ladroue C, Bell BA, Griffiths JR, Howe FA: Linear discriminant analysis of brain tumour (1)H MR spectra: a comparison of classification using whole spectra versus metabolite quantification. NMR Biomed; 2007 Dec;20(8):763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linear discriminant analysis of brain tumour (1)H MR spectra: a comparison of classification using whole spectra versus metabolite quantification.
  • Many studies have been performed to create an objective decision support system, but there is not yet a consensus as to the best techniques of MRS acquisition or data processing to be used for optimum classification.
  • In this study, we investigate whether LCModel analysis of short-TE (30 ms), single-voxel tumour spectra provide a better input for classification than the use of the original spectra.
  • A total of 145 histologically diagnosed brain tumour spectra were acquired [14 astrocytoma grade II (AS2), 15 astrocytoma grade III (AS3), 42 glioblastoma (GBM), 41 metastases (MET) and 33 meningioma (MNG)], and linear discriminant analyses (LDA) were performed on the LCModel analysis of the spectra and the original spectra.
  • The results consistently suggest improvement in classification when the LCModel concentrations are used.
  • Generally MNG spectra have profiles that are visually distinct from those of the other tumour types, but the classification accuracy was typically about 80%, with MNG with substantial lipid/macromolecule signals being classified as HG.
  • Omission of the lipid/macromolecule concentrations in the LCModel dataset provided an improvement in classification of MNG (91% compared with 76%).
  • However, the results suggest that a two-step LDA process may help in classifying the five tumour groups to provide optimum classification of MNG with high lipid/macromolecule contributions which maybe misclassified as HG.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17326043.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Kawai H, Ishikawa T, Moroi J, Hanyu N, Sawada M, Kobayashi N, Mutou T, Hikichi K, Suzuki A, Yasui N, Yoshida Y: [Elderly patient with cerebellar malignant astrocytoma]. No Shinkei Geka; 2008 Sep;36(9):799-805
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Elderly patient with cerebellar malignant astrocytoma].
  • Malignant cerebellar astrocytoma is very rare and the prognosis is extremely poor.
  • We report herein the case of an elderly patient with malignant cerebellar astrocytoma.
  • Metastatic cerebellar tumor was diagnosed on first admission, based on a past history of colon cancer treated by surgery and magnetic resonance imaging (MRI) findings supporting the diagnosis of metastasis.
  • The tumor represented malignant astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Cerebellar Neoplasms / surgery

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800635.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 19
  •  go-up   go-down


7. Pascual-Castroviejo I, Pascual-Pascual SI, Velázquez-Fragua R, Viaño J, Carceller F, Hernández-Moneo JL, Gutiérrez-Molina M, Morales C: [Subependymal giant cell astrocytoma in tuberous sclerosis complex. A presentation of eight paediatric patients]. Neurologia; 2010 Jun;25(5):314-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subependymal giant cell astrocytoma in tuberous sclerosis complex. A presentation of eight paediatric patients].
  • [Transliterated title] Astrocitoma subependimario de células gigantes en el complejo de esclerosis tuberosa. Presentación de ocho pacientes infantiles.
  • OBJECTIVE: Presentation of 8 patients with subependymal giant-cell astrocytomas (SGCA) associated with tuberous sclerosis complex (TSC).
  • [MeSH-major] Astrocytoma / etiology. Astrocytoma / pathology. Brain Neoplasms / etiology. Brain Neoplasms / pathology. Tuberous Sclerosis


8. Beckner ME, Gobbel GT, Abounader R, Burovic F, Agostino NR, Laterra J, Pollack IF: Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest; 2005 Dec;85(12):1457-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis.
  • Recently, we found that glycolytic enzymes were abundant and some were increased in pseudopodia formed by U87 glioma (astrocytoma) cells.
  • In this study, we examined cell migration, adhesion (a step in migration), and Matrigel invasion of U87 and LN229 glioma cells when their mitochondria were inhibited with sodium azide or limited by 1% O(2).
  • Upon discovering that glycolysis alone can support glioma cell migration, unique features of glucose metabolism in astrocytic cells were investigated.
  • The ability of astrocytic cells to remove lactate, the inhibitor of glycolysis, via gluconeogenesis and incorporation into glycogen led to consideration of supportive genetic mutations.
  • We hypothesize that glycolysis in gliomas can support invasive migration, especially when aided by loss of PTEN's regulation on the phosphatidylinositol-3 kinase (PI3K)/Akt pathway leading to inhibition of GSK3.
  • These findings confirm that glycolytic glioma cells can migrate invasively and that the loss of PTEN is supportive, with activated glycogenic potential included among the relevant downstream effects.
  • [MeSH-major] Astrocytoma / metabolism. Enzyme Inhibitors / pharmacology. Gluconeogenesis / drug effects. Glycogen Synthase Kinase 3 / metabolism. Glycolysis / physiology. PTEN Phosphohydrolase / pharmacology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors
  • [MeSH-minor] Cell Adhesion. Cell Line, Tumor. Cell Movement. Collagen. Drug Combinations. Gene Expression Regulation, Neoplastic. Humans. Lactic Acid / metabolism. Laminin. Mitochondria / drug effects. Mitochondria / metabolism. Neoplasm Invasiveness / physiopathology. Phosphorylation. Proteoglycans. RNA, Messenger / metabolism. Sodium Azide / pharmacology. Transfection

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SODIUM AZIDE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170333.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Enzyme Inhibitors; 0 / Laminin; 0 / Proteoglycans; 0 / RNA, Messenger; 119978-18-6 / matrigel; 33X04XA5AT / Lactic Acid; 9007-34-5 / Collagen; 968JJ8C9DV / Sodium Azide; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.26 / Glycogen Synthase Kinase 3; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


9. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H: Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome. Acta Neuropathol; 2009 Jun;117(6):653-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome.
  • Mutations of the IDH1 gene are frequent in gliomas, with R132H (CGT-->CAT) being the most common (>85%).
  • In astrocytomas, IDH1 mutations are typically co-present with, or precede, TP53 mutations.
  • We identified IDH1 mutations in five astrocytomas that developed in carriers of a TP53 germline mutation.
  • Without exception, all were R132C (CGT-->TGT), which in sporadic astrocytomas accounts for <5% of IDH1 mutations.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genes, p53. Isocitrate Dehydrogenase / genetics. Li-Fraumeni Syndrome / genetics


10. Rao RD, Krishnan S, Fitch TR, Schomberg PJ, Dinapoli RP, Nordstrom K, Scheithauer B, O'Fallon JR, Maurer MJ, Buckner JC: Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys; 2005 Feb 1;61(2):380-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
  • PURPOSE: To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma.
  • The primary study endpoint was the 23-month (700-day) survival, the median survival of patients with anaplastic astrocytoma in a previous North Central Cancer Treatment Group trial.
  • CONCLUSION: Our results have demonstrated that pre-RT chemotherapy with this regimen is insufficiently active in patients with anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy


11. Pollock JM, Whitlow CT, Tan H, Kraft RA, Burdette JH, Maldjian JA: Pulsed arterial spin-labeled MR imaging evaluation of tuberous sclerosis. AJNR Am J Neuroradiol; 2009 Apr;30(4):815-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient had a subependymal giant cell astrocytoma with a mean perfusion of 93.5 mL/100 g tissue/min.
  • CONCLUSIONS: The PASL technique can assess and quantify the perfusion characteristics of a cortical hamartoma.
  • [MeSH-minor] Adolescent. Astrocytoma / etiology. Astrocytoma / pathology. Brain Diseases / complications. Brain Diseases / pathology. Brain Neoplasms / etiology. Brain Neoplasms / pathology. Child. Child, Preschool. Disease Progression. Hamartoma / complications. Hamartoma / pathology. Humans. Infant. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147711.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / EB004673
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Spin Labels
  •  go-up   go-down


12. Bisland SK, Goebel EA, Hassanali NS, Johnson C, Wilson BC: Increased expression of mitochondrial benzodiazepine receptors following low-level light treatment facilitates enhanced protoporphyrin IX production in glioma-derived cells in vitro. Lasers Surg Med; 2007 Sep;39(8):678-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of mitochondrial benzodiazepine receptors following low-level light treatment facilitates enhanced protoporphyrin IX production in glioma-derived cells in vitro.
  • BACKGROUND AND OBJECTIVES: This study investigates whether low-level light treatment (LLLT) can enhance the expression of peripheral-type mitochondrial benzodiazepine receptors (PBRs) on glioma-derived tumor cells, and by doing so promote the synthesis of protoporphyrin IX (PpIX) and increase the photodynamic therapy (PDT)-induced cell kill using 5-aminolevulinic acid (ALA).
  • Cells of astrocytic derivation within the brain express PBRs, while neurons express the central-type of benzodiazepine receptor.
  • STUDY DESIGN: Astrocytoma-derived CNS-1 cells were exposed to a range of differing low-level light protocols immediately prior to PDT.
  • CONCLUSIONS: These data suggest that by selectively increasing PBR expression in tumor cells, LLLT facilitates enhanced tumor cell kill using ALA-PDT.
  • [MeSH-minor] Astrocytoma. Cell Cycle. Cell Survival. In Vitro Techniques. Microscopy, Confocal. Spectrometry, Fluorescence

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17886284.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-43892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protoporphyrins; 0 / Receptors, GABA; 0 / TSPO protein, human; 553-12-8 / protoporphyrin IX
  •  go-up   go-down


13. Abe T, Inoue R, Isono M, Ishii K, Fujiki M, Kamida T, Kobayashi H, Kashima K, Kusakabe T, Nakazato Y: Benign pleomorphic astrocytoma in the hypothalamus--case report. Neurol Med Chir (Tokyo); 2006 Feb;46(2):101-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pleomorphic astrocytoma in the hypothalamus--case report.
  • A 41-year-old woman presented with an unusual case of benign astrocytoma with marked pleomorphism manifesting as consciousness disturbance due to intraventricular hemorrhage.
  • Despite partial resection of the tumor without additional therapy, there have been no signs of tumor regrowth for 6 years.
  • The histological findings revealed solid proliferation of tumor cells with marked pleomorphism, contrary to the benign clinical course.
  • Immunohistochemical staining indicated the glial origin of the tumor.
  • The tumor was similar to pleomorphic xanthoastrocytoma, but the histological findings were not exactly identical, indicating a new histological entity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hypothalamus / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498222.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Wasilewski-Masker K, Liu Q, Yasui Y, Leisenring W, Meacham LR, Hammond S, Meadows AT, Robison LL, Mertens AC: Late recurrence in pediatric cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst; 2009 Dec 16;101(24):1709-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An increasing percentage of childhood cancer patients are surviving their disease, but there is limited research on late recurrence.
  • RESULTS: Overall, 5-year survivors of pediatric cancers experienced a cumulative incidence of recurrent disease of 4.4%, 5.6%, and 6.2% at 10, 15, and 20 years, respectively.
  • Cumulative incidence varied by diagnosis: Survivors of Ewing sarcoma and astrocytoma had the highest 20-year cumulative incidences at 13.0% (95% confidence interval [CI] = 9.4 to 16.5) and 14.4% (95% CI = 12.3 to 16.6), respectively.


15. Simon M, Neuloh G, von Lehe M, Meyer B, Schramm J: Insular gliomas: the case for surgical management. J Neurosurg; 2009 Apr;110(4):685-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insular gliomas: the case for surgical management.
  • OBJECT: Treatment for insular (paralimbic) gliomas is controversial.
  • RESULTS: A > 90% resection was achieved in 42%, and 70-90% tumor removal was accomplished in 51% of cases.
  • Surprisingly good survival rates were seen after surgery for anaplastic gliomas.
  • The median survival for patients with anaplastic astrocytomas (WHO Grade III) was 5 years, and the 5-year survival rate for those with anaplastic oligodendroglial tumors was 80%.
  • CONCLUSIONS: Insular tumor surgery carries substantial complication rates.
  • In view of the oncological benefits of resective surgery, our data would therefore argue for microsurgery as the primary treatment for most patients with a presumed WHO Grade I-III tumor.
  • [MeSH-major] Brain Neoplasms / surgery. Cerebral Cortex. Glioma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / surgery. Child. Female. Humans. Male. Middle Aged. Postoperative Complications. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099379.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Furneaux CE, Marshall ES, Yeoh K, Monteith SJ, Mews PJ, Sansur CA, Oskouian RJ, Sharples KJ, Baguley BC: Cell cycle times of short-term cultures of brain cancers as predictors of survival. Br J Cancer; 2008 Nov 18;99(10):1678-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain tumour material obtained at surgery from 70 patients with glioblastoma, medulloblastoma, astrocytoma, oligodendroglioma and metastatic melanoma was cultured for 7 days on 96-well plates, coated with agarose to prevent proliferation of fibroblasts.
  • Lower grade gliomas had longer median culture cycle times (16 days) than those of medulloblastomas (9.9 days), glioblastomas (9.8 days) or melanomas (6.7 days).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Kinetics. Male. Middle Aged. Prognosis. Survival Analysis. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2000 Jun;26(4):405-17 [10873364.001]
  • [Cites] Immunology. 2006 Oct;119(2):254-64 [17005005.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1566-75 [12432043.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Math Biol. 2003 Oct;47(4):295-312 [14523574.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):794-801 [15120035.001]
  • [Cites] Prog Biophys Mol Biol. 2004 Jun-Jul;85(2-3):353-68 [15142752.001]
  • [Cites] Oncol Res. 2004;14(6):297-304 [15206492.001]
  • [Cites] Cancer Treat Rep. 1978 Aug;62(8):1117-33 [356975.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 May;24(5):873-80 [3169092.001]
  • [Cites] Br J Cancer. 1988 Oct;58(4):423-31 [3207597.001]
  • [Cites] Br Med Bull. 1991 Jan;47(1):47-63 [1863848.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):340-5 [1738186.001]
  • [Cites] Eur J Cancer. 1995;31A(2):230-7 [7718330.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(2):140-7 [10398993.001]
  • [Cites] J Math Biol. 2004 Oct;49(4):329-57 [15657794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):505-11 [11173147.001]
  • (PMID = 18854836.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584938
  •  go-up   go-down


17. Attard TM, Giglio P, Koppula S, Snyder C, Lynch HT: Brain tumors in individuals with familial adenomatous polyposis: a cancer registry experience and pooled case report analysis. Cancer; 2007 Feb 15;109(4):761-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are at an increased risk of brain tumors, including cerebellar medulloblastoma, when compared with the general population (Brain Tumor Polyposis-BTP Type 2).
  • RESULTS: Twenty-eight patients from 24 families were accrued, the most common brain tumor in BTP was medulloblastoma (60%) predominantly in females (12:5) under the age of 20 (mean age 14.7 SD 9.2).
  • Other histologic subtypes included astrocytoma and ependymoma.
  • Analysis of the pooled APC mutation data by Chi-square test of association shows an odds ratio of 3.7 (P < .005) for all brain tumor subtypes and 13.1 (P < .001) for medulloblastoma in patients harboring segment 2 APC mutation (codons 679-1224) compared to nonsegment 2 mutation.


18. Rosenzweig T, Ziv-Av A, Xiang C, Lu W, Cazacu S, Taler D, Miller CG, Reich R, Shoshan Y, Anikster Y, Kazimirsky G, Sarid R, Brodie C: Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer Res; 2006 Apr 15;66(8):4139-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells.
  • In this study, we examined the expression and functions of related to testes-specific, vespid, and pathogenesis protein 1 (RTVP-1) in glioma cells.
  • RTVP-1 was expressed in high levels in glioblastomas, whereas its expression in low-grade astrocytomas and normal brains was very low.
  • Transfection of glioma cells with small interfering RNAs targeting RTVP-1 decreased cell proliferation in all the cell lines examined and induced cell apoptosis in some of them.
  • Overexpression of RTVP-1 increased astrocyte and glioma cell proliferation and the anchorage-independent growth of the cells.
  • In addition, overexpression of RTVP-1 rendered glioma cells more resistant to the apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand and serum deprivation.
  • Finally, we found that RTVP-1 regulated the invasion of glioma cells as was evident by their enhanced migration through Matrigel and by their increased invasion in a spheroid confrontation assay.
  • Our results suggest that the expression of RTVP-1 is correlated with the degree of malignancy of astrocytic tumors and that RTVP-1 is involved in the regulation of the growth, survival, and invasion of glioma cells.
  • Collectively, these findings suggest that RTVP-1 is a potential therapeutic target in gliomas.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioma / metabolism. Glioma / pathology. Neoplasm Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis
  • [MeSH-minor] Amino Acid Sequence. Apoptosis / physiology. Astrocytoma / enzymology. Astrocytoma / metabolism. Astrocytoma / pathology. Cell Growth Processes / physiology. Cell Line, Tumor. Cell Survival / physiology. Glioblastoma / enzymology. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Matrix Metalloproteinase 2 / metabolism. Molecular Sequence Data. Neoplasm Invasiveness


19. Popple RA, Griffith HR, Sawrie SM, Fiveash JB, Brezovich IA: Implementation of talairach atlas based automated brain segmentation for radiation therapy dosimetry. Technol Cancer Res Treat; 2006 Feb;5(1):15-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrated the utility of Brains2DICOM using a test case, a 34-year-old man with diffuse astrocytoma treated with three-dimensional conformal radiotherapy.
  • Further work is necessary to revise the ANN or to develop new methods for identification of small structures in the presence of disease and radiation induced changes.
  • [MeSH-minor] Adult. Anatomy, Artistic. Astrocytoma / radiotherapy. Humans. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Male. Medical Illustration. Neural Networks (Computer). Software

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417398.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Oh JW, Olman M, Benveniste EN: CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells. Biol Pharm Bull; 2009 Apr;32(4):573-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells.
  • Glioblastoma is the most malignant and common brain tumor.
  • To promote their growth, these glioma cells secrete a variety of soluble factors including plasminogen activator inhibitor-1 (PAI-1), which functions as an inhibitor of plasminogen activators.
  • We report here with the basis of microarray gene expression analysis that CXCR4 expressing glioma cells are capable of expressing PAI-1 mRNA and protein upon CXCL12 stimulation.
  • Interestingly, CXCL12 showed additive effects with another PAI-1 inducers, tumor necrosis factor (TNF)-alpha and/or tumor growth factor (TGF)-beta1, in increasing PAI-1 expression.
  • These results indicate that CXCL12/CXCR4 signaling in glioma cells may be another mechanism for these cells to express PAI-1, which may be involved in angiogenesis and tumor invasion in brain tumors.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Chemokine CXCL12 / physiology. Plasminogen Activator Inhibitor 1 / biosynthesis. Receptors, CXCR4 / physiology
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Enzyme Inhibitors / pharmacology. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Extracellular Signal-Regulated MAP Kinases / physiology. GTP-Binding Protein alpha Subunits, Gi-Go / metabolism. GTP-Binding Protein alpha Subunits, Gi-Go / physiology. Humans. In Situ Hybridization. Indicators and Reagents. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / physiology. Nuclease Protection Assays. Oligonucleotide Array Sequence Analysis. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / physiology. RNA, Complementary / biosynthesis. RNA, Complementary / genetics. Signal Transduction / drug effects. Signal Transduction / physiology. Transforming Growth Factor beta1 / pharmacology. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336886.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Chemokine CXCL12; 0 / Enzyme Inhibitors; 0 / Indicators and Reagents; 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Complementary; 0 / Receptors, CXCR4; 0 / Transforming Growth Factor beta1; 0 / Tumor Necrosis Factor-alpha; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gi-Go
  •  go-up   go-down


21. Morandi E, Zingaretti C, Chiozzotto D, Severini C, Semeria A, Horn W, Vaccari M, Serra R, Silingardi P, Colacci A: A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett; 2006 Jan 8;231(1):74-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chemotherapy, as generally available, is of a limited value in curing malignant brain tumors (gliomas), which often develop resistance to drugs, becoming completely unresponsive to any standard therapeutic approach.
  • We selected a CPT-resistant sub-line (U87CPT-R) from U87-MG grade III-IV astrocytoma cells, and compared the expression profile of the two cell lines by cDNA-microarray, as a preliminary screening of the molecular mechanisms involved in the acquisition of CPT resistance in glioma cells.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Brain Neoplasms / pathology. Camptothecin / pharmacology. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / drug effects. Glioblastoma / pathology
  • [MeSH-minor] Gene Expression Profiling. Humans. Inflammation. Neovascularization, Pathologic. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356833.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


22. Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK: Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther; 2010 May;9(5):1298-307
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.
  • Astrocytomas account for the majority of malignant brain tumors diagnosed in both adult and pediatric patients.
  • In this study, we found that Mer and Axl mRNA transcript and protein expression were elevated in astrocytic patient samples and cell lines. shRNA-mediated knockdown of Mer and Axl RTK expression led to an increase in apoptosis in astrocytoma cells.
  • Apoptotic signaling pathways including Akt and extracellular signal-regulated kinase 1/2, which have been shown to be activated in resistant astrocytomas, were downregulated with Mer and Axl inhibition whereas poly(ADP-ribose) polymerase cleavage was increased.
  • Furthermore, Mer and Axl shRNA knockdown led to a profound decrease of astrocytoma cell proliferation in soft agar and a significant increase in chemosensitivity in response to temozolomide, carboplatin, and vincristine treatment.
  • Our results suggest Mer and Axl RTK inhibition as a novel method to improve apoptotic response and chemosensitivity in astrocytoma and provide support for these oncogenes as attractive biological targets for astrocytoma drug development.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Dec 9;402(6762):672-6 [10604474.001]
  • [Cites] N Engl J Med. 2009 Oct 15;361(16):1570-83 [19828534.001]
  • [Cites] Nat Med. 2001 Feb;7(2):215-21 [11175853.001]
  • [Cites] Science. 2001 Jul 13;293(5528):306-11 [11452127.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1071-8 [12168903.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3470-7 [12177108.001]
  • [Cites] Curr Opin Immunol. 2003 Feb;15(1):31-6 [12495730.001]
  • [Cites] J Neurosci. 2003 May 15;23(10):4208-18 [12764109.001]
  • [Cites] Clin Exp Metastasis. 2003;20(7):665-74 [14669798.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Mar;85(6):1952-6 [3279421.001]
  • [Cites] Cell Growth Differ. 1994 Jun;5(6):647-57 [8086340.001]
  • [Cites] Mol Cell Biol. 1995 Dec;15(12):6582-92 [8524223.001]
  • [Cites] J Neurosurg. 1999 Mar;90(3):533-6 [10067924.001]
  • [Cites] Leukemia. 1999 Sep;13(9):1352-8 [10482985.001]
  • [Cites] J Clin Invest. 2005 Feb;115(2):237-46 [15650770.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neoplasia. 2005 Dec;7(12):1058-64 [16354588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5799-804 [16585512.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2662-9 [16675557.001]
  • [Cites] J Neurosci. 2006 May 24;26(21):5638-48 [16723520.001]
  • [Cites] Nat Immunol. 2006 Jul;7(7):747-54 [16751775.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Aug;65(8):769-75 [16896310.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6092-100 [16652142.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Dec;65(12):1181-8 [17146292.001]
  • [Cites] Neoplasma. 2007;54(4):334-41 [17822324.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):542-5 [17611390.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):130-8 [18172262.001]
  • [Cites] J Neurosci. 2008 Jan 2;28(1):264-78 [18171944.001]
  • [Cites] Cell. 2008 Jan 11;132(1):27-42 [18191218.001]
  • [Cites] Nat Rev Immunol. 2008 May;8(5):327-36 [18421305.001]
  • [Cites] Adv Cancer Res. 2008;100:35-83 [18620092.001]
  • [Cites] J Cell Physiol. 2008 Dec;217(3):584-9 [18651562.001]
  • [Cites] Mol Endocrinol. 2008 Nov;22(11):2481-95 [18787040.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4466-74 [18587011.001]
  • [Cites] Adv Tech Stand Neurosurg. 2009;34:3-35 [19368079.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):459-66 [19269895.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3442-55 [19633687.001]
  • [Cites] J Comp Neurol. 2000 Sep 18;425(2):295-314 [10954847.001]
  • (PMID = 20423999.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA082086-10; United States / NCI NIH HHS / CA / T32 CA082086; United States / NCI NIH HHS / CA / T32 CA082086-10
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; EC 2.7.10.1 / MERTK protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / axl receptor tyrosine kinase
  • [Other-IDs] NLM/ NIHMS304681; NLM/ PMC3138539
  •  go-up   go-down


23. Trivin C, Couto-Silva AC, Sainte-Rose C, Chemaitilly W, Kalifa C, Doz F, Zerah M, Brauner R: Presentation and evolution of organic central precocious puberty according to the type of CNS lesion. Clin Endocrinol (Oxf); 2006 Aug;65(2):239-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These were optic glioma or astrocytoma (n = 45), hydrocephalus (n = 22), hypothalamic hamartoma (n = 15), suprasellar arachnoid cyst (n = 10) and others (n = 8).
  • The boys with hamartoma were significantly taller and had greater bone age advance, LH peak and testosterone than boys with optic glioma.
  • All patients treated for optic glioma had hypothalamic-pituitary deficiencies, including GH (100%), thyrotrophin (71.4%), corticotrophin (12.5%) and pubertal (34.3%) deficiencies.
  • This is probably caused by differences in the mechanisms inducing puberty and to the hypothalamic-pituitary deficiencies associated with the CPP as a result of a lesion and/or its treatment.
  • [MeSH-major] Brain Neoplasms / complications. Hypothalamic Diseases / etiology. Pituitary Diseases / etiology. Puberty, Precocious / etiology
  • [MeSH-minor] Adolescent. Adult. Arachnoid Cysts / blood. Arachnoid Cysts / complications. Astrocytoma / blood. Astrocytoma / complications. Body Height. Child. Child, Preschool. Female. Follicle Stimulating Hormone / blood. Gonadal Steroid Hormones / blood. Growth Hormone / blood. Growth Hormone-Releasing Hormone. Hamartoma / blood. Hamartoma / complications. Humans. Hydrocephalus / blood. Hydrocephalus / complications. Hydrocortisone / blood. Hypothalamic Neoplasms / blood. Hypothalamic Neoplasms / complications. Luteinizing Hormone / blood. Male. Meningomyelocele / blood. Meningomyelocele / complications. Optic Nerve Glioma / blood. Optic Nerve Glioma / complications. Statistics, Nonparametric


24. Niranjan R, Kamat PK, Nath C, Shukla R: Evaluation of guggulipid and nimesulide on production of inflammatory mediators and GFAP expression in LPS stimulated rat astrocytoma, cell line (C6). J Ethnopharmacol; 2010 Feb 17;127(3):625-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of guggulipid and nimesulide on production of inflammatory mediators and GFAP expression in LPS stimulated rat astrocytoma, cell line (C6).
  • AIM OF THE STUDY: The present study was designed to investigate effect of guggulipid, a drug developed by CDRI and nimesulide on LPS stimulated neuroinflammatory changes in rat astrocytoma cell line (C6).
  • MATERIALS AND METHODS: Rat astrocytoma cells (C6) were stimulated with LPS (10 microg/ml) alone and in combinations with different concentrations of guggulipid or nimesulide for 24h of incubation.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Astrocytoma / metabolism. Glial Fibrillary Acidic Protein / metabolism. Inflammation / prevention & control. Inflammation Mediators / metabolism. Plant Extracts / pharmacology. Plant Gums / pharmacology. Sulfonamides / therapeutic use
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Antioxidants / therapeutic use. Cell Line, Tumor. Commiphora. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Down-Regulation. Gene Expression. Lipopolysaccharides. Nitrites / metabolism. Phytotherapy. RNA, Messenger / metabolism. Rats. Reactive Oxygen Species / metabolism. Tumor Necrosis Factor-alpha / genetics. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018235.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Glial Fibrillary Acidic Protein; 0 / Inflammation Mediators; 0 / Lipopolysaccharides; 0 / Nitrites; 0 / Plant Extracts; 0 / Plant Gums; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Sulfonamides; 0 / Tumor Necrosis Factor-alpha; 0 / guggulu extract; EC 1.14.99.1 / Cyclooxygenase 2; V4TKW1454M / nimesulide
  •  go-up   go-down


25. Terakawa Y, Morino M, Yamagata T, Ohata K: Extradural pneumatocele after temporal craniotomy: case report. Neurol Med Chir (Tokyo); 2008 Dec;48(12):576-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 22-year-old female first presented with a fibrillary astrocytoma in the left temporal region manifesting as complex partial seizure.
  • She underwent left temporal craniotomy to remove the tumor.
  • [MeSH-minor] Arachnoid Cysts / complications. Arachnoid Cysts / surgery. Astrocytoma / complications. Astrocytoma / surgery. Brain Neoplasms / complications. Brain Neoplasms / surgery. Epilepsy, Complex Partial / etiology. Epilepsy, Temporal Lobe / etiology. Female. Humans. Pressure. Temporal Lobe / surgery. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Chen YJ, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T, McDowell D, MacFarlane MR, Boet R, Baguley BC, Braithwaite AW, Reddel RR, Royds JA: Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res; 2006 Jul 1;66(13):6473-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma.
  • The molecular basis for alternative lengthening of telomeres (ALT), a prognostic marker for glioma patients, remains unknown.
  • We examined TP53 status in relation to telomere maintenance mechanism (TMM) in 108 patients with glioblastoma multiforme and two patients with anaplastic astrocytoma from New Zealand and United Kingdom.
  • Tumor samples were analyzed with respect to telomerase activity, telomere length, and ALT-associated promyelocytic leukemia nuclear bodies to determine their TMM.
  • We found an association between TP53 mutation and ALT mechanism and between wild-type TP53 and telomerase and absence of a known TMM (P < 0.0001).
  • [MeSH-major] Astrocytoma / genetics. Genes, p53. Glioblastoma / genetics. Mutation. Telomere / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818615.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Galderisi U, Cipollaro M, Giordano A: Stem cells and brain cancer. Cell Death Differ; 2006 Jan;13(1):5-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This raises the possibility that some features of tumor cells may be due to cancer stem cells.
  • Now, evidence has shown that brain cancers, such as glioblastomas, medulloblastomas and astrocytomas, also contain cells that may be multipotent neural stem cell-like cells.
  • [MeSH-minor] Animals. Biomarkers, Tumor / genetics. Cell Cycle. Cell Separation. Chromatin Assembly and Disassembly. Humans. Models, Biological


28. Kawarabuki K, Ohta T, Hashimoto N, Wada K, Maruno M, Yamaki T, Ueda S: Cerebellar glioblastoma genetically defined as a secondary one. Clin Neuropathol; 2005 Mar-Apr;24(2):64-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here the case of a 29-year-old woman with cerebellar glioblastma.
  • In the present case, tumor lesions were observed in each cerebellar hemisphere.
  • The left-side lesion was diagnosed as glioblastoma, and the right-side lesion as malignant astrocytoma by histopathology.
  • Immunohistochemistry revealed that the tumor cells of the left-side lesion was positive for p53, whereas epidermal growth factor receptors (EGFR) were negative in tumor cells from both sides.
  • Genetic alterations were investigated using a genome DNA microarray (GenoSensor Array 300), which has led us to define this tumor as a secondary glioblastoma.


29. Kabashi S, Muçaj S, Ahmetgjekaj I, Gashi S, Fazliu I, Dreshaj S, Shala N: Radiological imaging detection of tumors localized in fossa cranii posterior. Med Arh; 2008;62(5-6):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty-nine of them were found to have tumor localized in fossa crani posterior (FCP) without any significant difference between genders (50.8% female vs. 49.2% male, chi2 test=0.02 p=0.896).
  • Tumor types that more often were found in young's individuals were: Astrocytomas with a peak incidence in teenagers (average age was 12-year-old SD +/- 7.5, rank 3-23), next was Medulloblastomas (average age was 11-years-old, SD +/- 2.9, rank 6-16 years) and ependymomas (average age was 6.8-years-old, SD +/- 4.6, rank 1-12).
  • The most frequent tumors in children were medulloblastomas, brainstem gliomas, astrocytomas and ependymomas whereas meningiomas and metastasis were most often found in adults.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469268.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


30. Koos B, Peetz-Dienhart S, Riesmeier B, Frühwald MC, Hasselblatt M: O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas. Neuropathol Appl Neurobiol; 2010 Jun;36(4):356-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation is significantly less frequent in ependymal tumours as compared to malignant astrocytic gliomas.
  • [MeSH-major] Astrocytoma / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Ependymoma / genetics. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202118.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


31. Cosnard G, Duprez T, Grandin C, Hernalsteen D: [Intramedullary tumours and pseudotumours]. J Radiol; 2010 Sep;91(9 Pt 2):988-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These may also be seen in association with several diseases of inflammatory, infectious, granulomatous or vascular origin.
  • Characteristics: astrocytoma is lateral and infiltrative, ependymoma is central with white matter tract displacement and hemosiderin cap, hemangioblastoma is postero-lateral and shows enhancement with a vascular pedicle, metastases are very edematous or leptomeningeal in location.
  • [MeSH-major] Image Enhancement. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Spinal Cord Diseases / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adult. Astrocytoma / diagnosis. Contrast Media / administration & dosage. Diagnosis, Differential. Ependymoma / diagnosis. Female. Hemangioblastoma / diagnosis. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / etiology. Humans. Lymphoma / diagnosis. Myelitis / diagnosis. Myelitis / etiology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Spinal Cord Diseases.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814390.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


32. Boada M, Gómez E, Puig J, Pedraza S: [Intraventricular fibrous tumor: a case report]. Radiologia; 2009 Sep-Oct;51(5):512-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraventricular fibrous tumor: a case report].
  • [Transliterated title] Tumor fibroso intraventricular: a propósito de un caso.
  • Solitary fibrous tumor was first reported in the pleura; however, it has since been reported in many other locations.
  • To our knowledge, only eight cases of intraventricular solitary fibrous tumor have been reported.
  • We describe a case of intraventricular solitary fibrous tumor.The imaging characteristics of intraventricular solitary fibrous tumors are nonspecific; the differential diagnosis should include other tumors that can affect the ventricular system such as meningioma, high grade glioma, metastasis, subependymoma, choroid plexus papilloma, ependymoma, subependymal giant cell astrocytoma, and neurocytoma.
  • At histological study, immunohistochemical techniques allow solitary fibrous tumor to be differentiated from fibrous meningioma and hemangiopericytoma.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19646726.001).
  • [ISSN] 0033-8338
  • [Journal-full-title] Radiología
  • [ISO-abbreviation] Radiologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


33. Osztie E, Hanzély Z, Afra D: Lateral ventricle gliomas and central neurocytomas in adults diagnosis and perspectives. Eur J Radiol; 2009 Jan;69(1):67-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lateral ventricle gliomas and central neurocytomas in adults diagnosis and perspectives.
  • Neuroimaging data of lateral ventricle gliomas and central neurocytomas diagnosed in one institution were reviewed and compared to the corresponding literature data.
  • Eight subependymal giant cell astrocytomas also displayed hypodense, rarely hyperdense or mixed imaging characteristics, and always showed significant degree of contrast enhancement.
  • Ependymomas and anaplastic astrocytomas and glioblastomas followed the characteristics of the similar extraventricular ones.
  • In our series low-grade astrocytomas, WHO I-II [Louis DN, Ohgaki H, Wiestler OD, Canevee WK.
  • WHO classification of tumours of the central nervous system.
  • Lyon: International Agency for Research on Cancer; 2007] were hypodense without contrast uptake.
  • Our data support those of previous studies in that MRI has been found to be superior to CT for a more precise imaging of lateral ventricle gliomas.
  • Survival data were available in 65 cases, which have confirmed a favourable outcome in most of the patients with subependymoma, subependymal giant cell astrocytoma, central neurocytomas or pilocytic astrocytoma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Glioma / diagnosis. Magnetic Resonance Imaging / methods. Neurocytoma / diagnosis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023315.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


34. Isaac AO, Kawikova I, Bothwell AL, Daniels CK, Lai JC: Manganese treatment modulates the expression of peroxisome proliferator-activated receptors in astrocytoma and neuroblastoma cells. Neurochem Res; 2006 Nov;31(11):1305-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manganese treatment modulates the expression of peroxisome proliferator-activated receptors in astrocytoma and neuroblastoma cells.
  • We investigated the effects of manganese chloride treatment (0.01-4 mM) on protein expression of PPAR isoforms (alpha, beta, and gamma) in human astrocytoma (U87) and neuroblastoma (SK-N-SH) cells.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Manganese Poisoning / metabolism. Neuroblastoma / metabolism. Peroxisome Proliferator-Activated Receptors / biosynthesis
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cytosol / drug effects. Cytosol / metabolism. Humans. Immunoblotting. Nuclear Proteins / biosynthesis. Nuclear Proteins / genetics. PPAR alpha / metabolism. PPAR gamma / metabolism. PPAR-beta / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1999 Oct;20(5):649-88 [10529898.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):1239-47 [14988421.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32333-8 [15173181.001]
  • [Cites] Lancet. 1995 Jul 29;346(8970):270-4 [7630246.001]
  • [Cites] Scand J Work Environ Health. 1994 Aug;20(4):301-5 [7801076.001]
  • [Cites] J Neurosci Res. 2000 Jul 1;61(1):67-74 [10861801.001]
  • [Cites] Endocrinology. 2001 Oct;142(10):4195-202 [11564675.001]
  • [Cites] Biochem J. 2004 Aug 15;382(Pt 1):83-91 [15171682.001]
  • [Cites] Lancet. 1995 Mar 18;345(8951):735 [7885158.001]
  • [Cites] Neurotoxicology. 1999 Apr-Jun;20(2-3):433-44 [10385902.001]
  • [Cites] Neuroreport. 2001 Mar 26;12(4):839-43 [11277593.001]
  • [Cites] Methods Mol Biol. 2002;197:v-vi [12013816.001]
  • [Cites] Science. 1999 Apr 30;284(5415):757-60 [10221899.001]
  • [Cites] Int J Occup Environ Health. 2003 Apr-Jun;9(2):153-63 [12848244.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):98-104 [11205925.001]
  • [Cites] Toxicol Appl Pharmacol. 1992 Jul;115(1):1-5 [1631887.001]
  • [Cites] J Histochem Cytochem. 1979 Mar;27(3):735-45 [39097.001]
  • [Cites] J Neuroimmunol. 1999 Dec;100(1-2):156-68 [10695726.001]
  • [Cites] J Neurochem. 1998 Apr;70(4):1366-75 [9523552.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1046-52 [9734398.001]
  • [Cites] Brain Res. 1997 Jun 6;759(1):67-75 [9219864.001]
  • [Cites] Prog Neurobiol. 2000 Dec;62(6):561-81 [10880851.001]
  • [Cites] Science. 2003 May 9;300(5621):926-8 [12738847.001]
  • [Cites] Neurology. 1988 Apr;38(4):550-3 [3352909.001]
  • [Cites] J Neurocytol. 2001 Jan;30(1):21-33 [11577243.001]
  • [Cites] Science. 1988 Dec 9;242(4884):1412-5 [2849206.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):61-70 [14708026.001]
  • [Cites] J Neurosci Res. 2004 Jul 15;77(2):240-9 [15211590.001]
  • [Cites] Metab Brain Dis. 2002 Dec;17(4):375-87 [12602514.001]
  • [Cites] Neurochem Res. 2005 Nov;30(11):1369-75 [16341933.001]
  • [Cites] J Neurocytol. 2001 Aug;30(8):671-83 [12118155.001]
  • [Cites] J Neurochem. 1997 Nov;69(5):2132-7 [9349559.001]
  • [Cites] J Neurosci. 2000 Sep 15;20(18):6862-7 [10995830.001]
  • [Cites] Neurochem Res. 2004 Apr;29(4):709-17 [15098932.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):660-6 [12079514.001]
  • [Cites] Front Biosci. 2000 Mar 01;5:D298-306 [10704429.001]
  • [Cites] Mutat Res. 2000 Mar 17;448(2):121-38 [10725467.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):354-66 [8536636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):1052-60 [12065618.001]
  • [Cites] Exp Cell Res. 2005 Mar 10;304(1):91-104 [15707577.001]
  • [Cites] Science. 2000 Dec 15;290(5499):2140-4 [11118147.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12 ):7543-8 [11390509.001]
  • [Cites] Can J Physiol Pharmacol. 1997 Oct-Nov;75(10-11):1149-63 [9431439.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1129-38 [10706135.001]
  • (PMID = 17053972.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / P20RR016454
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / PPAR alpha; 0 / PPAR gamma; 0 / PPAR-beta; 0 / Peroxisome Proliferator-Activated Receptors
  •  go-up   go-down


35. Hocwald O, McFadden D, Osiovich H, Dunham C: Congenital gliosarcoma: detailed clinicopathologic documentation of a rare neoplasm. Pediatr Dev Pathol; 2009 Sep-Oct;12(5):398-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital gliosarcoma: detailed clinicopathologic documentation of a rare neoplasm.
  • Teratomas and astrocytomas appear to be the most common congenital neoplasms.
  • Amongst the latter, all grades and many subtypes are represented in the congenital time period, including the diffusely infiltrative forms of astrocytoma.
  • Gliosarcoma is currently considered a variant of glioblastoma (i.e., astrocytoma, World Health Organization grade IV) that exhibits genetically similar yet phenotypically separate histologic regions of high-grade astrocytoma and sarcoma.
  • We detail the case of a 1-day-old term male who presented with macrocrania, hydrocephalus, and signs of increased intracranial pressure.
  • Pathology revealed evidence of a classic gliosarcoma.

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883237.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Chu SH, Ma YB, Zhang H, Feng DF, Zhu ZA, Li ZQ, Yuan XH: Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells. J Neurooncol; 2007 Oct;85(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells.
  • Hepatocyte growth factor (HGF) is a pleiotrophic cytokine that stimulates motility and invasion of several cancer cell types and induces angiogenesis, which is known to be expressed in several malignancies including glioma.
  • The effect of transforming growth factor-beta (TGF-beta) isoforrns as well as gangliosides on HGF production was investigated in human glioma cell lines.
  • The ganglioside GD3 enhanced this release to the greatest extent and the stimulation was more marked in a glioblastoma cell line than in the two other anaplastic astrocytoma cell lines.
  • [MeSH-major] Brain Neoplasms / metabolism. Gangliosides / pharmacology. Glioma / metabolism. Hepatocyte Growth Factor / biosynthesis. Transforming Growth Factor beta / pharmacology
  • [MeSH-minor] Astrocytoma / metabolism. Cell Line, Tumor. Culture Media. Culture Media, Serum-Free. Enzyme-Linked Immunosorbent Assay. Humans. Isomerism. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Stimulation, Chemical

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] J Neurooncol. 2010 Apr;97(2):309 [20119650.001]
  • [Cites] Zhonghua Yi Xue Za Zhi. 2005 Mar 30;85(12):835-8 [15949402.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):203-15 [7533561.001]
  • [Cites] Cancer Lett. 1996 Jun 24;104(1):97-102 [8640753.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):143-9 [16648987.001]
  • [Cites] BMC Cardiovasc Disord. 2006 Apr 04;6:13 [16594992.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Apr;56(4):435-9 [9100674.001]
  • [Cites] Cancer Lett. 1996 Apr 19;102(1-2):209-15 [8603372.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2182-9 [16331629.001]
  • [Cites] Lab Invest. 1989 Dec;61(6):629-34 [2481152.001]
  • [Cites] Brain. 2006 Sep;129(Pt 9):2416-25 [16891318.001]
  • [Cites] Virchows Arch. 1999 Mar;434(3):201-5 [10190298.001]
  • [Cites] Eur Cytokine Netw. 2003 Jan-Mar;14(1):40-51 [12799213.001]
  • [Cites] Lab Invest. 1992 Dec;67(6):711-5 [1281244.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Jun 15;102(1-2):73-82 [12191496.001]
  • [Cites] Biochemistry. 1991 Mar 12;30(10):2563-70 [1848091.001]
  • [Cites] Cell Struct Funct. 1992 Jun;17(3):185-90 [1386559.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5392-7 [10537325.001]
  • [Cites] Eur Biophys J. 2003 Jul;32(4):381-91 [12851796.001]
  • [Cites] Hinyokika Kiyo. 2000 Oct;46(10):769-74 [11215208.001]
  • [Cites] World J Gastroenterol. 2002 Jun;8(3):496-8 [12046078.001]
  • [Cites] Diabetologia. 2000 Jun;43(6):763-72 [10907122.001]
  • [Cites] Exp Neurol. 2001 Apr;168(2):300-9 [11259118.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):533-8; discussion 538 [16720163.001]
  • [Cites] Neuropathol Appl Neurobiol. 1990 Dec;16(6):489-500 [1982895.001]
  • [Cites] Int J Cancer. 1999 Jul 30;82(3):449-58 [10399964.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4243-7 [2440560.001]
  • [Cites] J Neurochem. 1993 Jan;60(1):99-105 [8417168.001]
  • [Cites] Neurosurgery. 1992 Sep;31(3):541-9 [1407435.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1988;43:126-9 [2850730.001]
  • [Cites] J Neurochem. 2006 Sep;98(6):1973-84 [16911584.001]
  • [Cites] J Surg Res. 2007 Aug;141(2):284-8 [17561117.001]
  • [Cites] Neurosci Lett. 1995 Feb 15;186(1):53-6 [7783949.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):177-85 [11716069.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):287-93 [10873600.001]
  • [Cites] J Cell Physiol. 1990 Sep;144(3):505-10 [2391380.001]
  • [Cites] Neurosurgery. 2003 Jun;52(6):1391-9; discussion 1399 [12762884.001]
  • [Cites] Eur J Cancer. 1996 May;32A(5):868-71 [9081368.001]
  • [Cites] J Hypertens. 1996 Sep;14(9):1067-72 [8986905.001]
  • [Cites] J Immunol. 1992 Mar 1;148(5):1404-10 [1538124.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Feb 19;87(1):100-8 [11223164.001]
  • [Cites] Mol Chem Neuropathol. 1995 Feb-Apr;24(2-3):121-35 [7632317.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2154-61 [11280780.001]
  • [Cites] Clin Neuropathol. 2005 Jan-Feb;24(1):13-8 [15696779.001]
  • [Cites] Neuroscience. 1999;93(3):1041-9 [10473269.001]
  • [Cites] Prostate. 1999 Nov 1;41(3):145-53 [10517872.001]
  • (PMID = 17464449.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media; 0 / Culture Media, Serum-Free; 0 / Gangliosides; 0 / Transforming Growth Factor beta; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


37. Hamir AN, Picton R, Blythe LL, Heidel JR: Diagnostic exercise: astrocytoma with involvement of medulla oblongata, spinal cord, and spinal nerves in a raccoon (Procyon lotor). Vet Pathol; 2008 Nov;45(6):949-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic exercise: astrocytoma with involvement of medulla oblongata, spinal cord, and spinal nerves in a raccoon (Procyon lotor).
  • Described are clinical signs and pathologic and immunohistochemical findings in an adult female raccoon (Procyon lotor) with an astrocytoma that involved medulla, cervical spinal cord, and roots of the cervical spinal nerves.
  • This appears to be the only reported case of astrocytoma that involved multiple anatomic sites in the central nervous system of this raccoon.
  • [MeSH-major] Astrocytoma / veterinary. Central Nervous System Neoplasms / veterinary. Medulla Oblongata / pathology. Raccoons. Spinal Cord / pathology. Spinal Nerves / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984803.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Diwan R, Jain B, Kapoor N: Assessment of prognosis of astrocytoma: is reticulin stain helpful? Indian J Pathol Microbiol; 2006 Jul;49(3):472-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of prognosis of astrocytoma: is reticulin stain helpful?
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Reticulin / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001928.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Reticulin
  •  go-up   go-down


39. Cheong JH, Kim CH, Kim JM, Oh YH: Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report. Clin Neurol Neurosurg; 2010 Oct;112(8):701-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of intracranial anaplastic astrocytoma associated with neurofibromatosis type I into gliosarcoma: case report.
  • Gliosarcoma is an uncommon malignant brain tumor composed of distinct sarcomatous and malignant glial cell elements.
  • We report a rare case with gliosarcomatous recurrence of anaplastic astrocytoma with neurofibromatosis type 1 (NF-1) followed by chemoradiation therapy.
  • He underwent an osteoplastic craniotomy with total tumor resection.
  • Histopathology of the tumor showed findings corresponding with anaplastic astrocytoma.
  • MRI showed tumor recurrence in the original site of the tumor.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Neurofibromatosis 1 / pathology


40. Zadeh MD, Amini R, Firoozray M, Derakhshandeh-Peykar P: Frequent homozygous deletion of p16/CDKN2A gene in malignant gliomas of Iranian patients. Pak J Biol Sci; 2007 Dec 1;10(23):4246-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent homozygous deletion of p16/CDKN2A gene in malignant gliomas of Iranian patients.
  • Homozygous deletion is the main mechanism of CDKN2A gene inactivation in malignant gliomas.
  • In order to find the homozygous deletion frequency among Iranian patients, we have analyzed the status of CDKN2A gene in 40 malignant gliomas and examined their lalpha and 2 exons by comparative multiplex Polymerase Chain Reaction (PCR), using D9S171 chromosomal marker as an internal control.
  • We found homozygous deletion in 6 out of 7 cases (85.7%) of anaplastic astrocytomas and 20 out of 33 cases (60.6%) of glioblastoma multiforme, in total 26 out of 40 cases (65%) of malignant gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Deletion. Genes, p16. Glioma / genetics. Homozygote

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19086579.001).
  • [ISSN] 1028-8880
  • [Journal-full-title] Pakistan journal of biological sciences : PJBS
  • [ISO-abbreviation] Pak. J. Biol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


41. Smith D, Shimamura T, Barbera S, Bejcek BE: NF-kappaB controls growth of glioblastomas/astrocytomas. Mol Cell Biochem; 2008 Jan;307(1-2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NF-kappaB controls growth of glioblastomas/astrocytomas.
  • NF-kappaB is a family of transcription factors that have been shown to be elevated in a variety of tumor types and in some cases central to their survival and growth.
  • [MeSH-major] Astrocytoma / pathology. Cell Proliferation. Glioblastoma / pathology. NF-kappa B / physiology
  • [MeSH-minor] Cell Line, Tumor. Disease Progression. Gene Expression Regulation, Neoplastic / drug effects. Genes, rel. Humans. Platelet-Derived Growth Factor / genetics. RNA Interference. RNA, Small Interfering / pharmacology. Transcription Factor RelA / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1994 May 27;269(21):15337-43 [8195171.001]
  • [Cites] Mol Cell Biol. 1993 Dec;13(12):7203-12 [8246942.001]
  • [Cites] J Neurosurg. 2002 May;96(5):909-17 [12005399.001]
  • [Cites] Mol Biol Cell. 1992 Dec;3(12 ):1339-52 [1493333.001]
  • [Cites] Genes Dev. 2001 Sep 15;15(18):2321-42 [11562344.001]
  • [Cites] Oncogene. 1998 Mar 12;16(10 ):1229-39 [9546424.001]
  • [Cites] Leukemia. 2000 Mar;14 (3):399-402 [10720133.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):6939-43 [7688466.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):509-17 [8264620.001]
  • [Cites] Mol Biol Cell. 1993 Jan;4(1):49-57 [8443409.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14 ):3468-74 [10416612.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6926-36 [8943348.001]
  • [Cites] Cell Cycle. 2004 Sep;3(9):1114-7 [15492502.001]
  • [Cites] FEBS Lett. 2000 Sep 8;481(1):3-7 [10984605.001]
  • [Cites] J Biol Chem. 1998 Mar 6;273(10):5908-15 [9488729.001]
  • [Cites] EMBO J. 1992 Nov;11(11):3911-9 [1396585.001]
  • [Cites] J Pathol. 1998 Jan;184(1):44-52 [9582526.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3569-76 [9270030.001]
  • [Cites] Biochim Biophys Acta. 1991 Apr 16;1072(1):63-80 [2018779.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):21215-22 [8063742.001]
  • [Cites] EMBO J. 1993 Dec;12 (12 ):4685-95 [8223478.001]
  • [Cites] Nat Cell Biol. 2000 May;2(5):302-9 [10806482.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5763-7 [3039506.001]
  • [Cites] EMBO J. 1993 Jun;12(6):2257-64 [7685273.001]
  • [Cites] Mol Cell Biol. 1994 Oct;14(10):6715-26 [7935391.001]
  • [Cites] Cell. 1996 Oct 4;87(1):13-20 [8858144.001]
  • [Cites] Cell. 1990 Aug 10;62(3):481-92 [1696179.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7389-94 [10602496.001]
  • [Cites] Oncogene. 1996 Aug 15;13(4):731-7 [8761294.001]
  • [Cites] Immunity. 1995 Sep;3(3):263-72 [7552992.001]
  • [Cites] J Cell Physiol. 1995 Nov;165(2):239-45 [7593201.001]
  • [Cites] Mol Cell Biol. 1988 Jul;8(7):2753-62 [3405217.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):247-52 [2991148.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2690-8 [10082535.001]
  • [Cites] Exp Cell Res. 2002 Mar 10;274(1):157-67 [11855867.001]
  • [Cites] Annu Rev Cell Biol. 1987;3:443-92 [3318882.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2573-81 [10873114.001]
  • [Cites] Microb Pathog. 1998 Jul;25(1):33-41 [9705247.001]
  • [Cites] Biotechniques. 2001 Mar;30(3):504-6, 508 [11252786.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):512-6 [11331881.001]
  • [Cites] Nat Cell Biol. 2001 May;3(5):517-21 [11331882.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9011-8 [9083025.001]
  • [Cites] Biomaterials. 2002 Jul;23(13):2773-81 [12059028.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3729-35 [12097282.001]
  • [Cites] Mol Cell Biol. 1991 Feb;11(2):1125-32 [1703628.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2952-60 [9399940.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] BMC Cancer. 2007 Apr 03;7:59 [17407600.001]
  • [Cites] Cell. 1991 Apr 5;65(1):75-82 [1849460.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):301-10 [12001991.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):86-90 [10485711.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] EMBO J. 1988 May;7(5):1387-93 [2842148.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):42144-50 [12198114.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30942-9 [8940081.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):126-33 [9935242.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14 ):3032-9 [9230219.001]
  • (PMID = 17828582.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Platelet-Derived Growth Factor; 0 / RELA protein, human; 0 / RNA, Small Interfering; 0 / Transcription Factor RelA
  •  go-up   go-down


42. Scarabino T, Giannatempo GM, Nemore F, Popolizio T, Stranieri A: Supratentorial low-grade gliomas. Neuroradiology. J Neurosurg Sci; 2005 Sep;49(3):73-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial low-grade gliomas. Neuroradiology.
  • A brain tumors can be reliably ruled out, if the standard magnetic resonance examination is performed properly and experts interpret the results as negative for tumor.
  • In this paper we will illustrate morphological aspects of low-grade supratentorial neoplasms, including tumors of neuroepithelial tissue, such as low-grade diffuse fibrillary astrocytomas, and circumscribed astrocytic lesions (pilocytic astrocytoma, pleomorphic xantoastrocytoma and subependymal giant cell astrocytoma).
  • [MeSH-major] Glioma / diagnostic imaging. Glioma / pathology. Magnetic Resonance Imaging. Supratentorial Neoplasms / diagnostic imaging. Supratentorial Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288189.001).
  • [ISSN] 0390-5616
  • [Journal-full-title] Journal of neurosurgical sciences
  • [ISO-abbreviation] J Neurosurg Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


43. Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J: Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol; 2005 Feb;71(3):319-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.
  • PURPOSE: To assess the effectiveness of re-irradiation in recurrent low-grade gliomas (LGG).
  • PATIENTS AND METHODS: Sixty-three patients were treated with fractionated stereotactic re-irradiation in the case of recurrent gliomas.
  • At primary diagnosis of the tumor, the histology was grade II astrocytoma, oligodendroglioma or oligoastrocytoma.
  • CONCLUSION: Our retrospective data suggest that stereotactically guided fractionated re-irradiation in recurrent glioma represents an effective treatment option with good results and few complications.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Dose Fractionation. Glioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):996-1003 [14575830.001]
  • [Cites] Cancer. 1993 Jul 1;72 (1):190-5 [8508405.001]
  • [Cites] Eur J Cancer. 1998 Jan;34(1):98-102 [9624245.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1784-91 [8082081.001]
  • [Cites] Semin Radiat Oncol. 2001 Apr;11(2):145-51 [11285552.001]
  • [Cites] Arch Neurol. 1989 Nov;46(11):1238-9 [2818260.001]
  • [Cites] Arch Neurol. 1990 Oct;47(10):1138-40 [2222248.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):919-27 [3967199.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1998 May;64(5):581-7 [9598670.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):232-8 [12865907.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):853-61 [2715812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1405-9 [2542195.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):236-48 [8153667.001]
  • [Cites] Can J Surg. 1993 Jun;36(3):271-5 [8391917.001]
  • [Cites] Radiother Oncol. 2000 Nov;57(2):215-23 [11054526.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):393-8 [9069312.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1294-301 [9193320.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1402-3 [10751245.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):646-51 [12586801.001]
  • [Cites] Radiologe. 1995 Sep;35(9):583-6 [8588040.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):719-27 [8040017.001]
  • [Cites] J Neurosurg. 1984 Oct;61(4):665-73 [6470776.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12 ):2305-11 [12805331.001]
  • [Cites] Neurosurgery. 1987 Nov;21(5):615-21 [2827052.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1133-41 [10613305.001]
  • [Cites] J Neurosurg. 1993 Jun;78(6):909-14 [8487073.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):370-9 [9010111.001]
  • [Cites] Oncology. 2000 Feb;58(2):108-16 [10705237.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):977-82 [10192343.001]
  • [Cites] Neurology. 1999 Sep 22;53(5):1141-3 [10496285.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Semin Surg Oncol. 2001 Jan-Feb;20(1):13-23 [11291128.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4 [14765378.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):291-6 [8795601.001]
  • [Cites] Neurology. 2000 Apr 11;54(7):1442-8 [10751254.001]
  • [Cites] Clin Neurosurg. 1995;42:488-94 [8846613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurosurgery. 1996 May;38(5):872-8; discussion 878-9 [8727811.001]
  • [Cites] Radiology. 1996 Oct;201(1):275-8 [8816559.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1937-45 [8137221.001]
  • (PMID = 15735924.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Katsetos CD, Dráberová E, Smejkalová B, Reddy G, Bertrand L, de Chadarévian JP, Legido A, Nissanov J, Baas PW, Dráber P: Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells. Neurochem Res; 2007 Aug;32(8):1387-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that the neuronal-associated class III beta-tubulin isotype and the centrosome-associated gamma-tubulin are aberrantly expressed in astrocytic gliomas (Cell Motil Cytoskeleton 2003, 55:77-96; J Neuropathol Exp Neurol 2006, 65:455-467).
  • Here we determined the expression, distribution and interaction of betaIII-tubulin and gamma-tubulin in diffuse-type astrocytic gliomas (grades II-IV) (n = 17) and the human glioblastoma cell line T98G.
  • By immunohistochemistry and immunofluorescence microscopy, betaIII-tubulin and gamma-tubulin were co-distributed in anaplastic astrocytomas and glioblastomas and to a lesser extent, in low-grade diffuse astrocytomas (P < 0.05).
  • [MeSH-minor] Adult. Antineoplastic Agents, Phytogenic / pharmacology. Cell Line, Tumor / cytology. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Child. Humans. Multiprotein Complexes. Nocodazole / pharmacology. Paclitaxel / pharmacology. Tubulin Modulators / pharmacology. Vinblastine / pharmacology

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):479-85 [11914626.001]
  • [Cites] FEBS Lett. 2000 May 4;473(1):19-23 [10802051.001]
  • [Cites] J Clin Invest. 1997 Sep 1;100(5):1282-93 [9276747.001]
  • [Cites] Bull Cancer. 2005 Feb;92 (2):E25-30 [15749640.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] J Cell Sci. 2001 Jan;114(Pt 2):413-22 [11148142.001]
  • [Cites] Folia Biol (Praha). 1999;45(4):163-5 [10732731.001]
  • [Cites] Histochemistry. 1988;89(5):485-92 [2459085.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):562-6 [9484812.001]
  • [Cites] J Cell Sci. 1993 Dec;106 ( Pt 4):1263-73 [7907338.001]
  • [Cites] J Immunol. 2006 Jun 15;176(12 ):7243-53 [16751367.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Nov;52(6):655-66 [8229085.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12902-7 [15695826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4685-9 [2052551.001]
  • [Cites] Exp Cell Res. 2004 May 1;295(2):375-86 [15093737.001]
  • [Cites] Cell Motil Cytoskeleton. 1996;33(1):38-51 [8824733.001]
  • [Cites] Biochem J. 2002 Aug 1;365(Pt 3):889-95 [11939909.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):535-44 [10747310.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):7195-9 [2402501.001]
  • [Cites] Plant Cell. 2003 Feb;15(2):465-80 [12566585.001]
  • [Cites] Cell Motil Cytoskeleton. 1990;17(2):118-32 [2257630.001]
  • [Cites] Nature. 2005 May 26;435(7041):523-7 [15917813.001]
  • [Cites] Cell Motil Cytoskeleton. 2003 Jun;55(2):77-96 [12740870.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1187-91 [12946225.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):80-3 [1538786.001]
  • [Cites] Histochem Cell Biol. 1998 Mar;109(3):231-9 [9541471.001]
  • [Cites] J Cell Biochem. 2002;84(3):472-83 [11813253.001]
  • [Cites] Nature. 1995 Dec 7;378(6557):578-83 [8524390.001]
  • [Cites] Cell Motil Cytoskeleton. 1997;36(2):179-89 [9015205.001]
  • [Cites] Biochemistry. 1999 Nov 30;38(48):15712-20 [10625437.001]
  • [Cites] J Cell Biol. 1998 Aug 10;142(3):775-86 [9700165.001]
  • [Cites] Mol Chem Neuropathol. 1992 Dec;17(3):273-87 [1337253.001]
  • [Cites] J Cell Physiol. 1979 Apr;99(1):43-54 [222778.001]
  • [Cites] J Comp Neurol. 2000 Jul 31;423(3):359-72 [10870078.001]
  • [Cites] Dev Dyn. 2002 Mar;223(2):229-40 [11836787.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):465-77 [16772870.001]
  • [Cites] J Child Neurol. 2003 Dec;18(12):851-66; discussion 867 [14736079.001]
  • [Cites] Int J Oncol. 2005 Mar;26(3):589-96 [15703812.001]
  • [Cites] Acta Neuropathol. 2003 Jan;105(1):1-13 [12471454.001]
  • [Cites] Oncogene. 2002 Sep 9;21(40):6234-40 [12214254.001]
  • [Cites] Anat Rec. 1998 Mar;250(3):335-43 [9517850.001]
  • [Cites] J Cell Biol. 1999 Feb 22;144(4):721-33 [10037793.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):298-305 [15671559.001]
  • [Cites] Mol Biol Cell. 2000 Apr;11(4):1225-39 [10749926.001]
  • [Cites] Arch Pathol Lab Med. 2001 May;125(5):613-24 [11300931.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Apr;61(4):307-20 [11939586.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2078-85 [17285590.001]
  • [Cites] Nature. 1995 Dec 7;378(6557):638-40 [8524401.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Exp Cell Res. 2004 Aug 1;298(1):218-28 [15242776.001]
  • (PMID = 17406983.001).
  • [ISSN] 0364-3190
  • [Journal-full-title] Neurochemical research
  • [ISO-abbreviation] Neurochem. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Multiprotein Complexes; 0 / TUBB3 protein, human; 0 / Tubulin; 0 / Tubulin Modulators; 5V9KLZ54CY / Vinblastine; P88XT4IS4D / Paclitaxel; SH1WY3R615 / Nocodazole
  •  go-up   go-down


45. Mishra MK, Kumawat KL, Basu A: Japanese encephalitis virus differentially modulates the induction of multiple pro-inflammatory mediators in human astrocytoma and astroglioma cell-lines. Cell Biol Int; 2008 Dec;32(12):1506-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Japanese encephalitis virus differentially modulates the induction of multiple pro-inflammatory mediators in human astrocytoma and astroglioma cell-lines.
  • We have shown that Japanese encephalitis virus (JEV) infection causes morphological and functional changes in astrocytic cell-lines.
  • [MeSH-minor] Animals. Animals, Newborn. Astrocytoma / immunology. Brain Neoplasms / immunology. Cell Line, Transformed. Cell Line, Tumor. Ceruloplasmin / immunology. Ceruloplasmin / metabolism. Chemokines / immunology. Chemokines / metabolism. Cytokines / immunology. Cytokines / metabolism. Encephalitis Virus, Japanese / immunology. Humans. Mice. Mice, Inbred BALB C. Reactive Oxygen Species / immunology. Reactive Oxygen Species / metabolism. Thioredoxins / immunology. Thioredoxins / metabolism. Vesicular Glutamate Transport Proteins / immunology. Vesicular Glutamate Transport Proteins / metabolism

  • Genetic Alliance. consumer health - Japanese encephalitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801452.001).
  • [ISSN] 1095-8355
  • [Journal-full-title] Cell biology international
  • [ISO-abbreviation] Cell Biol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chemokines; 0 / Cytokines; 0 / Reactive Oxygen Species; 0 / Vesicular Glutamate Transport Proteins; 52500-60-4 / Thioredoxins; EC 1.16.3.1 / Ceruloplasmin
  •  go-up   go-down


46. Birlik B, Canda S, Ozer E: Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas. Neuropathol Appl Neurobiol; 2006 Oct;32(5):532-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour vascularity is of prognostic significance in adult, but not paediatric astrocytomas.
  • Astrocytomas are the commonest type of brain tumours in adults and children.
  • Due to the evidence that vascular changes are important histological features of astrocytomas, the aim of this study was to investigate prognostic significance of tumour vascularity in paediatric and adult astrocytomas.
  • Study population consisted of 70 patients (45 adult and 25 children) with histologically proven diagnosis of astrocytoma with no history of previous therapy.
  • Histological classification and grading were also assessed using the World Health Organization system.
  • In contrast to the results in paediatric astrocytomas, tumour vascularity in adult tumours correlated significantly with postoperative survival by univariate analysis (P < 0.05).
  • We conclude that histological quantification of tumour vascularity is a significant prognosticator in adult astrocytomas, but not in children.
  • Our data do not support the validity of applications of antiangiogenic agents in paediatric astrocytic tumours, particularly pilocytic astrocytomas.
  • [MeSH-major] Aging / pathology. Astrocytoma / blood supply. Astrocytoma / pathology. Brain Neoplasms / blood supply. Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972887.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antigens, CD31
  •  go-up   go-down


47. Ardeshiry Lajimi A, Rezaie-Tavirani M, Mortazavi SA, Barzegar M, Moghadamnia SH, Rezaee MB: Study of Anti Cancer Property of Scrophularia striata Extract on the Human Astrocytoma Cell Line (1321). Iran J Pharm Res; 2010;9(4):403-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of Anti Cancer Property of Scrophularia striata Extract on the Human Astrocytoma Cell Line (1321).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24381605.001).
  • [ISSN] 1735-0328
  • [Journal-full-title] Iranian journal of pharmaceutical research : IJPR
  • [ISO-abbreviation] Iran J Pharm Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3870064
  • [Keywords] NOTNLM ; 1321 cell line / Anticancer effect / Astrocytoma / Flow cytometry / Scrophularia striata extract
  •  go-up   go-down


48. Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, Prados MD: Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol; 2006 Jan;8(1):12-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area.
  • We compare survival estimates for population-based glioma cases by using two diagnostic coding schemes, (1) the International Classification of Diseases, Oncology, second edition (ICD-O-2) as reported by the Surveillance, Epidemiology, and End Results (SEER) program and (2) central neuropathology review diagnosis based on the World Health Organization II classification.
  • Eligible cases included adults residing in the San Francisco Bay SEER Area with newly diagnosed, histologically confirmed glioma during the years 1991-1994 and 1997-1999.
  • The study group included participating subjects for whom subsequent central neuropathology review confirmed glioma.
  • Survival differences between anaplastic astrocytoma (AA) and astrocytoma were apparent from review diagnoses (median months of survival for AA, 13.0 [95% CI, 9.9-19.5], and astrocytoma, 101.3 [95% CI lower limit, 42.1; upper limit not yet reached]), but not with ICD-O-2 diagnoses reported by SEER (median months of survival for AA, 16.6 [95% CI, 12.0-20.7], and astrocytoma, not otherwise specified, 17.2 [95% CI, 10.6-71.6]).
  • This finding emphasizes the need for improvements in coding for nonglioblastoma astrocytomas to provide better population survival estimates.
  • Further consideration of impact of marital status, education, and other social factors in glioma survival may be warranted.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2000;6(1):46-52 [10749588.001]
  • [Cites] Can J Neurol Sci. 1998 Aug;25(3):197-201 [9706720.001]
  • [Cites] Pediatr Neurosurg. 2000 Jun;32(6):321-6 [10971194.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):963-9 [11029499.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2447-54 [9796977.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1617-22 [9815964.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3031-5 [9865917.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2241-7 [10070294.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):203-11 [10363853.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):581-94 [10517935.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):675-80 [15542975.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2040-4 [16103458.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):635-40 [11148662.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1299-308 [12973855.001]
  • [Cites] Patient Educ Couns. 1999 Jul;37(3):215-30 [14528548.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1220-3 [14973082.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2618-25 [15102663.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2567-75 [15226324.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Eur J Epidemiol. 2004;19(6):533-40 [15330125.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Eur J Cancer Prev. 2004 Oct;13(5):397-401 [15452452.001]
  • [Cites] J Psychosom Res. 2004 Aug;57(2):123-31; discussion 133-5 [15465065.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neurooncol. 1994;18(1):69-81 [8057137.001]
  • [Cites] Cancer Causes Control. 1995 May;6(3):240-56 [7612804.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Neurol Clin. 1996 May;14(2):273-90 [8827171.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):796-803 [9024718.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1673-7 [9135006.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Cancer. 2000 May 15;88(10):2342-9 [10820357.001]
  • (PMID = 16443944.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES06717; United States / NIEHS NIH HHS / ES / R01 ES006717; United States / NCI NIH HHS / CA / R01 CA089032; United States / NCI NIH HHS / CA / CA89032; United States / NIEHS NIH HHS / ES / ES04705; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / CA52689; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1871921
  •  go-up   go-down


49. Wu PS, Yao WJ: F-18 FDG PET in spinal cord pilocytic astrocytoma. Clin Nucl Med; 2010 Aug;35(8):649-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG PET in spinal cord pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Spinal Cord Neoplasms / radionuclide imaging

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631528.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


50. Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S: Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg; 2007 Apr;106(4):575-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases.
  • OBJECT: The purpose of this retrospective study was to estimate the prognostic impact of treatment parameters for 170 patients with anaplastic astrocytoma (AA).
  • Resection of as much of the tumor as possible and delivery of a total radiation dose of greater than 60 Gy seem to be required for local control of AA.
  • [MeSH-major] Astrocytoma / radiotherapy. Astrocytoma / surgery. Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432706.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Omura Y, Horiuchi N, Jones MK, Lu DP, Shimotsuura Y, Duvvi H, Pallos A, Ohki M, Suetsugu A: Temporary anti-cancer & anti-pain effects of mechanical stimulation of any one of 3 front teeth (1st incisor, 2nd incisor, & canine) of right & left side of upper & lower jaws and their possible mechanism, & relatively long term disappearance of pain & cancer parameters by one optimal dose of DHEA, Astragalus, Boswellia Serrata, often with press needle stimulation of True ST. 36. Acupunct Electrother Res; 2009;34(3-4):175-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One minute downward pressure on the tip of any one of the front 3 teeth (1st incisor, 2nd incisor, and canine) at the right and left sides of the upper and lower jaw by a wooden toothpick induced temporary disappearance (20 min approximately 4 hours) of abnormally increased pain parameters (pain grading, Substance P, & TXB2), and cancer parameters (Telomere, Integrin alpha5beta1, Oncogene C-fos Ab2, etc. of Astrocytoma, Glioblastoma, squamous cell carcinoma of esophagus, adenocarcinoma of lung, breast cancer, adenocarcinoma of colon, prostate cancer).
  • Increasing NC telomere to optimally high level resulted in disappearance of pain and improvement or significant reduction of malignant tumor.
  • One optimal dose of Boswellia Serrata or Astragalus not only increased NC telomere 650 ng BDORT units, eliminating pain and cancer parameters, but also reduced the size of the Astrocytoma grade I by 10-20% and the Glioblastoma by 15-90% in less than 2-6 months in some patients, as long as high NC telomere is maintained.

  • MedlinePlus Health Information. consumer health - Acupuncture.
  • MedlinePlus Health Information. consumer health - Pain.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20344885.001).
  • [ISSN] 0360-1293
  • [Journal-full-title] Acupuncture & electro-therapeutics research
  • [ISO-abbreviation] Acupunct Electrother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


52. El-Bahy K: Telovelar approach to the fourth ventricle: operative findings and results in 16 cases. Acta Neurochir (Wien); 2005 Feb;147(2):137-42; discussion 142
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inferior medullary velum was infiltrated by the tumour and was not detected as a separate layer in 6 cases (3 cases vermian astrocytomas and 3 cases medulloblastomas).
  • Subtotal removal was achieved in the remaining patients (31.25%); three ependymomas, one medulloblastoma, and one anaplastic astrocytoma.
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / pathology. Astrocytoma / surgery. Cerebellar Ataxia / etiology. Cerebellar Ataxia / pathology. Cerebellar Ataxia / physiopathology. Child. Choroid Plexus / pathology. Choroid Plexus / surgery. Cranial Fossa, Posterior / surgery. Dermoid Cyst / pathology. Dermoid Cyst / surgery. Ependymoma / pathology. Ependymoma / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Medulloblastoma / pathology. Medulloblastoma / surgery. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Papilloma, Choroid Plexus / pathology. Papilloma, Choroid Plexus / surgery. Postoperative Complications / etiology. Postoperative Complications / pathology. Postoperative Complications / physiopathology. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15605202.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


53. Khanlou N, Mathern GW, Mitchell WG, Salamon N, Pope WB, Yong WH, Vinters HV: Cortical dysplasia with prominent Rosenthal fiber formation in a case of intractable pediatric epilepsy. Hum Pathol; 2009 Aug;40(8):1200-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 5-year-old boy with intractable epilepsy who underwent therapeutic corticectomy.
  • Rosenthal fiber proliferation may represent a reactive process, are frequent in pilocytic astrocytomas, and are a defining feature of Alexander disease.
  • There was no evidence of neoplasm or leukodystrophy in this case.
  • [MeSH-major] Alexander Disease / diagnosis. Cerebral Cortex / abnormalities. Epilepsies, Partial / pathology. Malformations of Cortical Development / diagnosis. Nerve Fibers, Myelinated / pathology

  • Genetic Alliance. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXCARBAZEPINE .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427021.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS38992
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Glial Fibrillary Acidic Protein; 33CM23913M / Carbamazepine; VZI5B1W380 / oxcarbazepine
  •  go-up   go-down


54. Chamberlain MC, Chowdhary SA, Glantz MJ: Anaplastic astrocytomas: biology and treatment. Expert Rev Neurother; 2008 Apr;8(4):575-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic astrocytomas: biology and treatment.
  • Anaplastic astrocytomas (AA), WHO grade III gliomas, comprise 10-15% of all glial neoplasms.
  • Evidence-based management of patients with AA supports maximum safe resection followed by involved-field radiotherapy for newly diagnosed patients, and temozolomide for recurrent disease.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Clinical Trials as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416660.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Grunwald I, Dillmann K, Roth C, Backens M, Reith W: [Supratentorial tumors]. Radiologe; 2007 Jun;47(6):471-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging is a routine diagnostic measure for a suspected intracerebral mass.
  • Further diagnostic procedures as well as the interpretation of the findings vary depending on the tumor location.
  • Supratentorial tumors include astrocytoma, differentiated by their circumscribed and diffuse growth, ganglioglioma, ependyoma, neurocytoma, primitive neuroectodermal tumors (PNET), oligodendroglioma, dysem-bryoplastic neuroepithelial tumors (DNET), meningoangiomatosis, pineal tumors, hamatoma, lymphoma, craniopharyngeoma and metastases.
  • The most common sub-forms, especially of astrocytoma, will also be presented.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2006 Jun;22(6):577-85 [16555075.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):146-55 [15222000.001]
  • [Cites] Pediatr Dev Pathol. 1999 Nov-Dec;2(6):582-7 [10508884.001]
  • [Cites] J Neurosurg Sci. 2005 Sep;49(3):73-6 [16288189.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):292-7 [12750935.001]
  • [Cites] Neurology. 1996 Jun;46(6):1669-73 [8649567.001]
  • [Cites] Childs Nerv Syst. 1998 Aug;14(8):357-61 [9753400.001]
  • [Cites] Nat Clin Pract Neurol. 2007 Jan;3(1):24-35 [17205072.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Neurooncol. 2001 Sep;54(3):251-61 [11767291.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10):1839-41 [10588106.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):85-93 [16418363.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):61-78 [9210053.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Sep;22(8):1632 [11559521.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):635-9 [16078078.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Australas Radiol. 2005 Oct;49(5):433-7 [16174188.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(7):829-31 [10955682.001]
  • [Cites] Mo Med. 1990 Dec;87(12):889-91 [2270072.001]
  • [Cites] Neurocirugia (Astur). 2005 Dec;16(6):518-22 [16378134.001]
  • [Cites] Childs Nerv Syst. 2003 Sep;19(9):650-4 [12720031.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Dec;57(12):1497-502 [7798980.001]
  • [Cites] J Comput Assist Tomogr. 2004 May-Jun;28(3):407-13 [15100549.001]
  • [Cites] Arq Neuropsiquiatr. 2006 Sep;64(3A):613-8 [17119805.001]
  • [Cites] J Neuroimaging. 2006 Jan;16(1):52-8 [16483277.001]
  • [Cites] Childs Nerv Syst. 2006 May;22(5):514-6 [16369853.001]
  • [Cites] Cell Tissue Res. 2002 Dec;310(3):257-70 [12457224.001]
  • [Cites] J Neurooncol. 1999;44(3):275-81 [10720207.001]
  • [Cites] Neurology. 1998 Oct;51(4):1046-50 [9781527.001]
  • [Cites] J Nippon Med Sch. 2000 Oct;67(5):388-91 [11031374.001]
  • [Cites] Neurology. 2002 Sep 24;59(6):947-9 [12297589.001]
  • [Cites] Neuroradiology. 1992;34(3):173-8 [1630604.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):595-604 [15497113.001]
  • [Cites] Radiology. 2003 Jul;228(1):193-9 [12832582.001]
  • [Cites] Neuroradiology. 2006 Jan;48(1):1-7 [16237548.001]
  • [Cites] AJR Am J Roentgenol. 1998 Mar;170(3):804-5 [9490984.001]
  • [Cites] Cancer Imaging. 2006 Oct 31;6:S178-84 [17114073.001]
  • [Cites] Radiographics. 2002 Sep-Oct;22(5):1177-89 [12235346.001]
  • [Cites] Curr Neurol Neurosci Rep. 2003 May;3(3):193-9 [12691623.001]
  • [Cites] Curr Opin Neurol. 1993 Dec;6(6):882-7 [8293162.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):1-10 [10866344.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Arch Iran Med. 2007 Apr;10 (2):194-8 [17367223.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Am J Dis Child. 1988 May;142(5):486 [3358385.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S10-23; discusssion S1-4 [16237282.001]
  • [Cites] Eur Radiol. 2002 Jul;12 (7):1829-36 [12111075.001]
  • [Cites] Expert Rev Neurother. 2006 Apr;6(4):519-32 [16623651.001]
  • [Cites] Clin Radiol. 2006 Apr;61(4):348-57 [16546465.001]
  • [Cites] Australas Radiol. 2000 Nov;44(4):460-3 [11103549.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • [Cites] J Neurooncol. 2006 May;78(1):59-62 [16314940.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Dec;6(12 ):1200-14 [16370386.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Sep;21(8):1470-7 [11003281.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):1-7 [8817411.001]
  • [Cites] Cancer J. 2006 Jan-Feb;12(1):1-13 [16613654.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E7 [16048293.001]
  • [Cites] Clin Neurol Neurosurg. 2006 Jun;108(4):363-8 [15893874.001]
  • [Cites] J Belge Radiol. 1994 Oct;77(5):221 [7961378.001]
  • (PMID = 17541538.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


56. Hardell L, Carlberg M: Mobile phones, cordless phones and the risk for brain tumours. Int J Oncol; 2009 Jul;35(1):5-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regarding astrocytoma we found highest risk for ipsilateral mobile phone use in the >10 year latency group, OR=3.3, 95% CI=2.0-5.4 and for cordless phone use OR=5.0, 95% CI=2.3-11.
  • The annual age-adjusted incidence of astrocytoma for the age group >19 years increased significantly by +2.16%, 95% CI +0.25 to +4.10 during 2000-2007 in Sweden in spite of seemingly underreporting of cases to the Swedish Cancer Registry.
  • [MeSH-minor] Adult. Age Distribution. Age Factors. Aged. Astrocytoma / etiology. Case-Control Studies. Female. Humans. Incidence. Logistic Models. Male. Meningioma / etiology. Middle Aged. Neuroma, Acoustic / etiology. Odds Ratio. Prognosis. Registries. Risk Assessment. Risk Factors. Surveys and Questionnaires. Sweden / epidemiology. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19513546.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


57. Gomes AL, Reis-Filho JS, Lopes JM, Martinho O, Lambros MB, Martins A, Schmitt F, Pardal F, Reis RM: Molecular alterations of KIT oncogene in gliomas. Cell Oncol; 2007;29(5):399-408
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular alterations of KIT oncogene in gliomas.
  • Gliomas are the most common and devastating primary brain tumours.
  • Despite therapeutic advances, the majority of gliomas do not respond either to chemo or radiotherapy.
  • In the present study we assessed the frequency of KIT overexpression in gliomas and investigated the genetic mechanisms underlying KIT overexpression.
  • KIT (CD117) immunohistochemistry was performed in a series of 179 gliomas of various grades.
  • Tumour cell immunopositivity was detected in 15.6% (28/179) of cases, namely in 25% (1/4) of pilocytic astrocytomas, 25% (5/20) of diffuse astrocytomas, 20% (1/5) of anaplastic astrocytomas, 19.5% (15/77) of glioblastomas and one third (3/9) of anaplastic oligoastrocytomas.
  • In conclusion, our results demonstrate that KIT gene amplification rather than gene mutation is a common genetic mechanism underlying KIT expression in subset of malignant gliomas.
  • Further studies are warranted to determine whether glioma patients exhibiting KIT overexpression and KIT gene amplification may benefit from therapy with anti-KIT RTK inhibitors.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Glioma / genetics. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726262.001).
  • [ISSN] 1570-5870
  • [Journal-full-title] Cellular oncology : the official journal of the International Society for Cellular Oncology
  • [ISO-abbreviation] Cell. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4618227
  •  go-up   go-down


58. Zhen L, Yufeng C, Zhenyu S, Lei X: Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature. J Neurooncol; 2010 May;97(3):451-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracranial metastasis of glioblastoma multiforme (GBM) is very rare, in spite of very aggressive tumor behavior and being documented in only a few patients.
  • Histology revealed a diffuse astrocytoma (grade II).
  • The tumor recurred 1 year later and the patient received a second craniotomy.
  • [MeSH-minor] Adult. Craniotomy / methods. Humans. Magnetic Resonance Imaging. Male. Receptor, Epidermal Growth Factor / metabolism. S100 Proteins / metabolism. Tomography, X-Ray Computed / methods. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1990 Jul 1;66(1):180-4 [2162242.001]
  • [Cites] Cancer. 1978 Dec;42(6):2854-64 [215298.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer. 1976 Mar;37(3):1577-83 [177171.001]
  • [Cites] Acta Cytol. 1993 Nov-Dec;37(6):938-42 [8249517.001]
  • [Cites] Brain Pathol. 1996 Jul;6(3):217-23; discussion 23-4 [8864278.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Clin Exp Neurol. 1987;23:111-7 [2822301.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Jul;118(7):755-6 [1320896.001]
  • [Cites] Cancer. 1980 Jan 1;45(1):112-25 [6985826.001]
  • [Cites] J Neurosurg. 1969 Jul;31(1):50-8 [4307543.001]
  • [Cites] J Neurosurg. 1970 Jul;33(1):88-94 [4316740.001]
  • [Cites] J Korean Med Sci. 2001 Aug;16(4):481-8 [11511795.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Nov-Dec;17 (10 ):1929-31 [8933881.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11(1):1-26 [6203642.001]
  • [Cites] J Neurosurg. 1985 Jun;62(6):918-21 [2987441.001]
  • [Cites] Ann Neurol. 1980 Dec;8(6):605-8 [6260012.001]
  • (PMID = 19898745.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 19
  •  go-up   go-down


59. Kim YA, Kim GY, Park KY, Choi YH: Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia. J Med Food; 2007 Jun;10(2):218-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure of cultured rat C6 astroglioma cells to LPS increased their release of NO and PGE2 and their inducible expression of NO synthase and cyclooxygenase-2, all of which were significantly inhibited by resveratrol pretreatment.
  • These results demonstrate a potent suppressive effect of resveratrol on pro-inflammatory responses of microglia by modulation of NF-kappaB activity, suggesting a therapeutic potential for this compound in neurodegenerative diseases accompanied by microglial activation.
  • [MeSH-minor] Animals. Astrocytoma. Cell Division / drug effects. Cell Line, Tumor. Cell Nucleus / metabolism. Cyclooxygenase 2 / genetics. Gene Expression / drug effects. NF-kappa B / metabolism. Nitric Oxide Synthase Type II / genetics. Rats

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. RESVERATROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651055.001).
  • [ISSN] 1096-620X
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Stilbenes; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone; Q369O8926L / resveratrol
  •  go-up   go-down


60. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H: WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol; 2007 Aug;114(2):111-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?
  • We investigated the expression of APM components in astrocytomas without detectable defects in HLA class I antigen expression and correlated it with grade of malignancy.
  • Quantitative immunohistochemical analysis of astrocytomas revealed reduced expression of the cytosolic proteasome subunit low molecular weight protein 2 (LMP2), the endoplasmatic reticulum (ER) transporter associated with antigen processing-1 (TAP1), and the ER chaperone beta2-microglobulin (beta2m) in astrocytoma cells when compared to astrocytes from nonpathological brain.
  • Among human WHO grade II-IV astrocytomas, downregulation of LMP2, TAP1 and beta2m correlated with grade of malignancy.
  • Furthermore, astrocytoma cell lines (n = 12) expressed all APM components analyzed at levels comparable to dendritic cells (DC), which were used for comparative purposes.
  • However, upregulation of beta2m after stimulation with inflammatory cytokines was significantly lower in astrocytoma cell lines than in control cells.
  • Our results support the hypothesis that coordinated downregulation or impaired upregulation of certain HLA class I APM components may serve as a mechanism for astrocytoma cells to evade the host's immune response, even if HLA class I antigen surface expression is not altered.
  • [MeSH-major] Antigen Presentation / immunology. Astrocytoma / immunology. Brain Neoplasms / immunology. Histocompatibility Antigens Class I / metabolism. Tumor Escape / immunology
  • [MeSH-minor] ATP-Binding Cassette Sub-Family B Member 2. ATP-Binding Cassette Transporters / biosynthesis. Adolescent. Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Child. Child, Preschool. Cysteine Endopeptidases / biosynthesis. Down-Regulation. Female. Flow Cytometry. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. World Health Organization. beta 2-Microglobulin / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541610.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Sub-Family B Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Histocompatibility Antigens Class I; 0 / TAP1 protein, human; 0 / beta 2-Microglobulin; 144416-78-4 / LMP-2 protein; EC 3.4.22.- / Cysteine Endopeptidases
  •  go-up   go-down


61. Aryan HE, Meltzer HS, Lu DC, Ozgur BM, Levy ML, Bruce DA: Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature. Childs Nerv Syst; 2005 Jun;21(6):477-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of pilocytic astrocytoma with diffuse leptomeningeal spread: two cases and review of the literature.
  • INTRODUCTION: Leptomeningeal dissemination of juvenile pilocytic astrocytoma (JPA) is a rare event.
  • We report two children with disseminated JPAs treated with a chemotherapeutic agent, temozolomide, after progression of the disease despite surgery, traditional chemotherapy, and/or radiation therapy.
  • CASE REPORTS: Patient 1 presented with hydrocephalus and progressive lower extremity weakness, and was found to have a suprasellar mass as well as extensive spinal disease.
  • Ventriculoperitoneal shunting, decompressive laminectomy with spinal tumor debulking, and chemotherapy with carboplatin and vincristine were initially employed.
  • However, disease progressed and craniospinal irradiation and temozolomide were used.
  • Imaging revealed a cystic lesion in the hypothalamic region with extensive subarachnoid metastatic disease to the spine.
  • Due to the continued progression of the disease, cytoreductive surgery was performed and her chemotherapeutic regimen was switched to temozolomide.
  • Two years after initial presentation patient 2 is clinically much improved with stable residual disease.
  • DISCUSSION: We review the literature and discuss treatment strategies for this challenging disease.
  • [MeSH-major] Arachnoid Cysts / therapy. Astrocytoma / therapy. Brain Neoplasms / therapy

  • Genetic Alliance. consumer health - Diffuse Astrocytoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):17-23 [9083697.001]
  • [Cites] J Neurosurg. 1994 Jul;81(1):24-30 [8207524.001]
  • [Cites] Ann Oncol. 2001 Feb;12 (2):259-66 [11300335.001]
  • [Cites] Neurosurg Rev. 1996;19(4):217-20 [9007882.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2671-3 [8194003.001]
  • [Cites] Childs Brain. 1976;2(3):177-86 [971637.001]
  • [Cites] Neurology. 1976 Apr;26(4):322-5 [944389.001]
  • [Cites] Clin Neuropathol. 1988 Sep-Oct;7(5):254-8 [3208464.001]
  • [Cites] J Neurosurg. 1978 Jan;48(1):34-41 [412924.001]
  • [Cites] Neurology. 1988 Apr;38(4):562-6 [3352911.001]
  • [Cites] Cancer. 1993 May 15;71(10 ):3165-72 [8490847.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):850-6 [8487049.001]
  • [Cites] Cancer. 1987 Mar 1;59(5):1000-4 [2434201.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):47-54 [8865002.001]
  • [Cites] J Neurosurg. 1981 Jan;54(1):128-32 [7463115.001]
  • [Cites] Br J Neurosurg. 1998 Feb;12(1):56-8 [11013652.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):259-65 [11718258.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Nov;97(4):300-6 [8599896.001]
  • [Cites] J Neurooncol. 2002 May;57(3):247-51 [12125988.001]
  • [Cites] Childs Brain. 1983;10(6):393-403 [6661937.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Surg Neurol. 1997 Jul;48(1):49-51; discussion 51-2 [9199684.001]
  • [Cites] Childs Nerv Syst. 1993 Sep;9(6):334-8 [8269416.001]
  • [Cites] J Neurosurg. 1991 Dec;75(6):972-5 [1941128.001]
  • [Cites] Childs Nerv Syst. 1998 Nov;14(11):617-22 [9840361.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):115-27 [11716065.001]
  • [Cites] J Neurosurg. 1992 Nov;77(5):788-91 [1403124.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2869-78 [8194029.001]
  • [Cites] Eur J Cancer. 2000 Sep;36(14 ):1788-95 [10974627.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):223-7 [8331404.001]
  • (PMID = 15378329.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; YF1K15M17Y / temozolomide
  • [Number-of-references] 34
  •  go-up   go-down


62. Learn CA, Grossi PM, Schmittling RJ, Xie W, Mitchell DA, Karikari I, Wei Z, Dressman H, Sampson JH: Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. J Neuroimmunol; 2007 Jan;182(1-2):63-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.
  • For the study of malignant glioma, we have previously characterized a highly tumorigenic murine astrocytoma, SMA-560, which arose spontaneously in an inbred, immunocompetent VM/Dk mouse.
  • Using this cell line as a model of murine glioma, we performed DNA microarray analysis of autologous normal murine astroctyes (NMA) and SMA-560 tumor cells grown in monolayer culture or intracranially in syngeneic immunocompetent or immunocompromised hosts in order to determine whether tumors grown in vitro recreate the complex genetic regulation that occurs in vivo.
  • Our findings support our hypothesis that glioma phenotype in vitro may be quite different in vivo and significantly altered by in situ growth factors and other invading cell populations.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimmunol. 1999 Oct 29;99(2):195-204 [10505975.001]
  • [Cites] J Neurovirol. 1998 Apr;4(2):148-58 [9584952.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8287-92 [15928080.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5292-9 [16033848.001]
  • [Cites] Mol Ther. 2005 Oct;12(4):585-98 [16095972.001]
  • [Cites] Leuk Lymphoma. 2005 Dec;46(12):1689-98 [16263570.001]
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):3-15 [16153857.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1391-6 [16263789.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3294-302 [16540683.001]
  • [Cites] Cancer Cell. 2006 May;9(5):391-403 [16697959.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4294-305 [16857805.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] J Neuroimmunol. 2000 Feb 1;103(1):16-25 [10674985.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7503-8 [10852962.001]
  • [Cites] Ann Neurol. 2002 Mar;51(3):393-405 [11891838.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):683-6 [12016138.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66 [12118559.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3496-502 [12429640.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4831-8 [15269159.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3216-24 [15131063.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):37-42 [15015573.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5316-26 [15328167.001]
  • [Cites] Acta Neuropathol. 1980;51(1):53-64 [7435141.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4375-82 [7671250.001]
  • [Cites] Cytokine. 1995 Aug;7(6):580-8 [8580376.001]
  • [Cites] Neurosurgery. 1997 Dec;41(6):1365-72; discussion 1372-3 [9402588.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):302-9 [9443409.001]
  • [Cites] Neuro Oncol. 2005 Jan;7(1):90-6 [15701286.001]
  • (PMID = 17137636.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NCI NIH HHS / CA / R01 CA097222; United States / NCI NIH HHS / CA / 1T32-CA-74736; United States / NCI NIH HHS / CA / CA-97222-0; United States / NCI NIH HHS / CA / T32 CA074736; United States / NCI NIH HHS / CA / 1P50CA108786-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS16766; NLM/ PMC1865509
  •  go-up   go-down


63. Nutt CL: Molecular genetics of oligodendrogliomas: a model for improved clinical management in the field of neurooncology. Neurosurg Focus; 2005 Nov;19(5):E2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oligodendrogliomas, in contrast to astrocytic gliomas, frequently respond to chemotherapy and have a better overall prognosis.
  • Furthermore, 1p/19q loss has been shown to correlate with unequivocal oligodendroglial tumor histology, location and growth pattern of tumors within the brain, and magnetic resonance imaging characteristics.
  • Although much is also known about the molecular pathological characteristics of astrocytic gliomas, the significance of this information to clinical management in patients with these tumors has not been as striking as has been the case for oligodendrogliomas; possible reasons for this are discussed.
  • [MeSH-minor] Disease Management. Humans. Medical Oncology / methods


64. Jóhannsdóttir IM, Hjermstad MJ, Moum T, Wesenberg F, Hjorth L, Schrøder H, Lähteenmäki P, Jónmundsson G, Loge JH: Social outcomes in young adult survivors of low incidence childhood cancers. J Cancer Surviv; 2010 Jun;4(2):110-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study objective was to assess social outcomes in early adulthood after successful treatment for childhood acute myeloid leukemia (AML), Wilms tumor (WT) and infratentorial astrocytoma (IA).
  • METHODS: Nordic patients treated for AML, WT and IA from 1985 to 2001 identified from a database administered by NOPHO (Nordic Society of Paediatric Haematology and Oncology) were invited to participate in a postal survey.
  • [MeSH-major] Astrocytoma / psychology. Infratentorial Neoplasms / psychology. Leukemia, Myeloid, Acute / psychology. Social Behavior. Survivors / psychology. Wilms Tumor / psychology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):60-3 [10401499.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jan;50(1):104-10 [17554791.001]
  • [Cites] Curr Probl Cancer. 2003 May-Jun;27(3):112-26 [12748581.001]
  • [Cites] Psychooncology. 2003 Apr-May;12(3):213-25 [12673806.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] Int J Cancer Suppl. 1999;12:25-31 [10679867.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):417-23 [19479971.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1751-60 [16130127.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):807-14 [18989157.001]
  • [Cites] Med Pediatr Oncol. 1999 Jul;33(1):29-33 [10401494.001]
  • [Cites] Curr Probl Cancer. 2003 Jul-Aug;27(4):177-97 [12855950.001]
  • [Cites] Psychosomatics. 1997 Jan-Feb;38(1):54-62 [8997117.001]
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4060-6 [11118467.001]
  • [Cites] J Cancer Surviv. 2008 Sep;2(3):205-14 [18663582.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3518-24 [17687156.001]
  • [Cites] J Cancer Surviv. 2008 Sep;2(3):149-58 [18792789.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2374-81 [19364956.001]
  • [Cites] Pediatr Hematol Oncol. 1997 Nov-Dec;14(6):513-24 [9383804.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Jan-Feb;16(1):9-21 [9932269.001]
  • [Cites] Med Pediatr Oncol. 1991;19(6):459-66 [1961132.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Acta Paediatr Scand. 1989 Sep;78(5):728-35 [2596279.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2390-5 [19224833.001]
  • [Cites] Pediatrics. 2007 Mar;119(3):554-68 [17332209.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):923-8 [15292930.001]
  • [Cites] Hum Reprod. 2008 Jan;23(1):178-86 [18024486.001]
  • [Cites] Lancet. 2000 Apr 15;355(9212):1310-4 [10776743.001]
  • [Cites] Lancet Oncol. 2008 Jun;9(6):569-76 [18510988.001]
  • [Cites] Pediatr Hematol Oncol. 1997 May-Jun;14(3):223-32 [9185207.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3392-9 [8490888.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):704-15 [16830322.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):1-11 [16718655.001]
  • [Cites] Psychooncology. 2007 Oct;16(10):920-7 [17279494.001]
  • [Cites] Cancer. 1986 Jul 15;58(2 Suppl):529-33 [3719547.001]
  • [Cites] J Dev Behav Pediatr. 2007 Dec;28(6):448-55 [18091089.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v119-27 [14684502.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1354-8 [8869099.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):229-34 [11838795.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jun;26(6):354-62 [15167348.001]
  • [Cites] Pediatr Hematol Oncol. 1998 Nov-Dec;15(6):479-88 [9842641.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):251-73, xiii [18242324.001]
  • [Cites] Support Care Cancer. 2002 Nov;10(8):579-600 [12436217.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jul;47(1):61-70 [16572415.001]
  • [Cites] Psychooncology. 2002 Mar-Apr;11(2):132-41 [11921329.001]
  • [Cites] CA Cancer J Clin. 2004 Jul-Aug;54(4):208-36 [15253918.001]
  • [Cites] Cancer. 2008 May 1;112(9):2071-9 [18327823.001]
  • [Cites] Pediatr Neurosurg. 2005 Jan-Feb;41(1):15-21 [15886508.001]
  • [Cites] Eur J Cancer. 2001 Aug;37(12):1523-7, discussion 1527-30 [11506960.001]
  • (PMID = 20082150.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A: Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother; 2008 Jul;57(7):987-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200.
  • CD200 expression on human tumor cells in animal models prevents human lymphocytes from rejecting the tumor; treatment with an antagonistic anti-CD200 antibody restored lymphocyte-mediated tumor growth inhibition.
  • METHODS AND RESULTS: CD200 protein was expressed on the surface of 5/8 ovarian cancer, 2/4 melanoma, 2/2 neuroblastoma and 2/3 renal carcinoma cell lines tested, but CD200 was absent on prostate, lung, breast, astrocytoma, or glioblastoma cell lines.
  • Addition of CD200-expressing, but not CD200-negative solid tumor cell lines to mixed lymphocyte reactions downregulated the production of Th1 cytokines.
  • CONCLUSION: These data suggest that melanoma, ccRCC and ovarian tumor cells can express CD200, thereby potentially suppressing anti-tumor immune responses.
  • CD200 blockade with an antagonistic antibody may permit an effective anti-tumor immune response in these solid tumor types.
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunohistochemistry. Lymphocyte Culture Test, Mixed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060403.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / antigens, CD200
  •  go-up   go-down


66. Yamamoto T, Kato Y, Kawaguchi-Niida M, Shibata N, Osawa M, Saito K, Kröger S, Kobayashi M: Characteristics of neurons and glia in the brain of Fukuyama type congenital muscular dystrophy. Acta Myol; 2008 Jul;27:9-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glycosylated alpha-dystroglycan is reduced in the glia limitans formed by astrocytic endfeet.
  • Slight accumulation of N(epsilon)-(carboxymethyl)lysine, an oxidative modification product, is observed in astrocytes of Fukuyama type congenital muscular dystrophy and in an astrocytoma cell line with suppressed fukutin expression.
  • Carboxymethyl lysine is accumulated in cortical neurons of a severe case of Fukuyama type congenital muscular dystrophy.
  • However, it is still unclear how the loss of fukutin causes astrocytic and neuronal dysfunction.

  • Genetic Alliance. consumer health - Congenital Muscular Dystrophy.
  • Genetic Alliance. consumer health - Fukuyama Type Muscular Dystrophy.
  • Genetic Alliance. consumer health - Muscular dystrophy.
  • MedlinePlus Health Information. consumer health - Muscular Dystrophy.
  • Hazardous Substances Data Bank. L-Lysine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3083-90 [11115853.001]
  • [Cites] Dev Biol. 2007 Jul 1;307(1):62-78 [17512925.001]
  • [Cites] Neurology. 2001 Jul 10;57(1):115-21 [11445638.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):422-5 [12140559.001]
  • [Cites] Acta Neuropathol. 2002 Sep;104(3):217-24 [12172906.001]
  • [Cites] J Child Neurol. 2002 Nov;17(11):793-9 [12585716.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 May;62(5):497-508 [12769189.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 20;306(1):93-7 [12788071.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):500-5 [14699049.001]
  • [Cites] Neuroscience. 2004;125(4):921-35 [15120852.001]
  • [Cites] Nature. 1998 Jul 23;394(6691):388-92 [9690476.001]
  • [Cites] Med Electron Microsc. 2004 Dec;37(4):200-7 [15614444.001]
  • [Cites] Neuromuscul Disord. 2005 Jun;15(6):416-26 [15907289.001]
  • [Cites] Brain Res. 2006 Feb 23;1075(1):223-8 [16466646.001]
  • [Cites] Semin Pediatr Neurol. 2005 Sep;12(3):152-8 [16584074.001]
  • [Cites] Semin Pediatr Neurol. 2006 Jun;13(2):80-9 [17027857.001]
  • [Cites] Biochem Soc Trans. 2006 Dec;34(Pt 6):1261-6 [17073798.001]
  • [Cites] Neurosci Res. 2006 Dec;56(4):391-9 [17005282.001]
  • [Cites] Development. 2007 May;134(9):1723-36 [17395644.001]
  • [Cites] J Neurochem. 2007 Jun;101(6):1712-22 [17326765.001]
  • [Cites] Glycobiology. 2001 Jan;11(1):37-45 [11181560.001]
  • (PMID = 19108571.001).
  • [ISSN] 1128-2460
  • [Journal-full-title] Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
  • [ISO-abbreviation] Acta Myol
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / FKTN protein, human; 0 / Membrane Proteins; 5746-04-3 / N(6)-carboxymethyllysine; K3Z4F929H6 / Lysine
  • [Number-of-references] 22
  • [Other-IDs] NLM/ PMC2859607
  •  go-up   go-down


67. Nakase H, Tamura K, Kim YJ, Hirabayashi H, Sakaki T, Hoshida T: Long-term follow-up outcome after surgical treatment for lesional temporal lobe epilepsy. Neurol Res; 2007 Sep;29(6):588-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuropathologic diagnoses were cavernoma in three cases, astrocytoma (grade 2) in two cases, arteriovenous malformation in two cases, gliosis in two cases and ganglioglioma in one case.

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17535567.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


68. Parlato C, Barbarisi M, Moraci M, Moraci A: Surgery, radiotherapy and temozolomide in treating high-grade gliomas. Front Biosci; 2006;11:1280-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
  • Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas.
  • The goal of this study is to determine the activity and safety of temozolomide in improving overall survival (OS), progression-free survival (PFS) and health-related quality of life (HQL) in patient with malignant gliomas treated by surgery, radiotherapy and temozolomide.
  • Twelve patients with newly diagnosed glioblastoma (GBM), and anaplastic astrocytoma (AA) were studied.
  • The overall response rate for all histological groups was 33% (4 patients), 6 patients (50%) showed a stabilization of disease.
  • The median progression-free survival (PFS) and overall survival (OS) was respectively 8.35 and 14.1 months; time to progression was 36 week ranging from 20 to 46 In all patients, treatment with temozolomide was associated with improvement of performance status including the patient showing disease progression; Karnofski score improved in all patients by a minimum of 10, with a median of 20 at 6 months.
  • Temozolomide appears to be an ideal, first-line, single-agent, with a safe profile and demonstrated HQL benefits in patients with high-grade gliomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / therapy. Combined Modality Therapy / methods. Dacarbazine / analogs & derivatives. Glioma / therapy
  • [MeSH-minor] Adult. Astrocytoma / therapy. Clinical Trials as Topic. Disease Progression. Disease-Free Survival. Female. Glioblastoma / therapy. Humans. Male. Middle Aged. Quality of Life. Radiotherapy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16368514.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


69. Camden JM, Schrader AM, Camden RE, González FA, Erb L, Seye CI, Weisman GA: P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. J Biol Chem; 2005 May 13;280(19):18696-702
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The amyloid precursor protein (APP) is proteolytically processed by beta- and gamma-secretases to release amyloid beta, the main component in senile plaques found in the brains of patients with Alzheimer disease.
  • Here it is demonstrated that activation of the G protein-coupled P2Y2 receptor (P2Y2R) subtype expressed in human 1321N1 astrocytoma cells enhanced the release of sAPP alpha in a time- and dose-dependent manner.
  • [MeSH-minor] ADAM Proteins. Amino Acid Chloromethyl Ketones / pharmacology. Amyloid Precursor Protein Secretases. Aspartic Acid Endopeptidases. Blotting, Western. Butadienes / pharmacology. Calcium / chemistry. Calcium / metabolism. Cell Line, Tumor. Central Nervous System / metabolism. Chelating Agents / pharmacology. Dose-Response Relationship, Drug. Down-Regulation. Furin / chemistry. Humans. Indoles / pharmacology. MAP Kinase Signaling System. Maleimides / pharmacology. Metalloendopeptidases / chemistry. Nitriles / pharmacology. Phorbol Esters / chemistry. Protein Kinase C / chemistry. Protein Structure, Tertiary. RNA, Small Interfering / metabolism. Receptors, Purinergic P2Y2. Tetradecanoylphorbol Acetate. Time Factors. Transfection. Uridine Triphosphate / chemistry

  • COS Scholar Universe. author profiles.
  • Guide to Pharmacology. gene/protein/disease-specific - P2Y2 receptor - data and references .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15778502.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / 1 P01-AG18357; United States / NCRR NIH HHS / RR / 1 P20-RR15565
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-oxodecyl-arginyl-valyl-lysyl-arginine chloromethyl ketone; 0 / Amino Acid Chloromethyl Ketones; 0 / Amyloid beta-Protein Precursor; 0 / Butadienes; 0 / Chelating Agents; 0 / Indoles; 0 / Maleimides; 0 / Nitriles; 0 / P2RY2 protein, human; 0 / Phorbol Esters; 0 / RNA, Small Interfering; 0 / Receptors, Purinergic P2; 0 / Receptors, Purinergic P2Y2; 0 / U 0126; 133052-90-1 / bisindolylmaleimide I; 526U7A2651 / Egtazic Acid; EC 2.7.11.13 / Protein Kinase C; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.- / Endopeptidases; EC 3.4.21.75 / Furin; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.46 / BACE1 protein, human; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.- / tumor necrosis factor-alpha convertase; K22DDW77C0 / 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; NI40JAQ945 / Tetradecanoylphorbol Acetate; SY7Q814VUP / Calcium; UT0S826Z60 / Uridine Triphosphate
  •  go-up   go-down


70. Warth A, Simon P, Capper D, Goeppert B, Tabatabai G, Herzog H, Dietz K, Stubenvoll F, Ajaaj R, Becker R, Weller M, Meyermann R, Wolburg H, Mittelbronn M: Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. J Neurosci Res; 2007 May 1;85(6):1336-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival.
  • Aquaporin-4 (AQP4), the most prominent CNS water channel, is restricted to the glia limitans and astrocytic endfeet.
  • To elucidate the AQP4 role in brain tumors, we investigated 189 WHO grade I-IV gliomas by immunohistochemistry and the prognostic significance for patients' survival.
  • In gliomas, a remarkable de novo AQP4 redistribution was observed in comparison with normal CNS tissue.
  • Surprisingly, the highest membraneous staining levels were seen in pilocytic astrocytomas WHO grade I and grade IV glioblastomas, both significantly higher than in WHO grade II astrocytomas.
  • Hence, AQP4 redistribution may go along with other tumor properties, such as vascular proliferation and resulting blood-brain barrier disturbance, features usually prominent in pilocytic astrocytomas WHO I and glioblastomas WHO grade IV.
  • In addition, our results provide unexpectedly high AQP4 levels in pilocytic astrocytomas and present AQP4 as tumor progression marker in WHO grade II-IV astrocytomas.
  • [MeSH-major] Aquaporin 4 / metabolism. Blood-Brain Barrier / physiopathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioma / metabolism. Glioma / pathology
  • [MeSH-minor] Brain / metabolism. Brain Edema / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic / physiology. Humans. Male. Multivariate Analysis. Proportional Hazards Models. Protein Array Analysis / methods. Severity of Illness Index. Sex Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17335082.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Aquaporin 4
  •  go-up   go-down


71. Spadaro E, Migliacci ML, Romano LM, Zoppi J: [Astrocytoma grade II. Atypical image]. Medicina (B Aires); 2008;68(4):305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Astrocytoma grade II. Atypical image].
  • [Transliterated title] Astrocitoma grado II. Imagen atípica.
  • [MeSH-major] Astrocytoma / pathology. Brain / pathology. Brain Neoplasms / pathology. Demyelinating Diseases / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786888.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


72. Lemire J, Mailloux RJ, Appanna VD: Mitochondrial lactate dehydrogenase is involved in oxidative-energy metabolism in human astrocytoma cells (CCF-STTG1). PLoS One; 2008;3(2):e1550
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial lactate dehydrogenase is involved in oxidative-energy metabolism in human astrocytoma cells (CCF-STTG1).
  • In this report, we demonstrate, for the first time, the ability of a human astrocytic cell line (CCF-STTG1) to consume lactate and to generate ATP via oxidative phosphorylation. (13)C-NMR and HPLC analyses aided in the identification of tricarboxylic acid (TCA) cyle metabolites and ATP in the astrocytic mitochondria incubated with lactate.
  • Taken together, this study implicates lactate as an important contributor to ATP metabolism in the brain, a finding that may significantly change our notion of how this important organ manipulates its energy budget.
  • [MeSH-major] Astrocytoma / metabolism. L-Lactate Dehydrogenase / metabolism. Mitochondrial Proteins / metabolism. Oxidative Phosphorylation
  • [MeSH-minor] Adenosine Triphosphate / metabolism. Cell Line, Tumor. Cell Respiration. Energy Metabolism. Humans. Lactic Acid / metabolism

  • Hazardous Substances Data Bank. LACTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cereb Blood Flow Metab. 2006 Jan;26(1):142-52 [15973352.001]
  • [Cites] Biochem Pharmacol. 2006 Feb 14;71(4):399-407 [16368075.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 Jun;290(6):E1237-44 [16434551.001]
  • [Cites] J Biochem Mol Toxicol. 2006;20(4):198-208 [16906525.001]
  • [Cites] Eur J Neurosci. 2006 Sep;24(6):1687-94 [17004932.001]
  • [Cites] Neuroscience. 2007 Mar 2;145(1):11-9 [17218064.001]
  • [Cites] Glia. 2007 Sep;55(12):1251-62 [17659524.001]
  • [Cites] Glia. 2007 Sep;55(12):1263-71 [17659525.001]
  • [Cites] PLoS One. 2007;2(8):e690 [17668068.001]
  • [Cites] Cell Physiol Biochem. 2007;20(5):627-38 [17762189.001]
  • [Cites] Adv Exp Med Biol. 1991;296:197-206 [1781326.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cryobiology. 1978 Apr;15(2):239-41 [352618.001]
  • [Cites] J Appl Physiol Respir Environ Exerc Physiol. 1984 May;56(5):1260-4 [6725086.001]
  • [Cites] Fed Proc. 1986 Dec;45(13):2924-9 [3536591.001]
  • [Cites] J Exp Med. 1987 Feb 1;165(2):500-14 [3102672.001]
  • [Cites] Pflugers Arch. 1991 Oct;419(3-4):230-4 [1745598.001]
  • [Cites] Anal Biochem. 1991 Dec;199(2):223-31 [1812789.001]
  • [Cites] Arch Biochem Biophys. 1994 Feb 1;308(2):515-9 [8109982.001]
  • [Cites] J Appl Physiol (1985). 1999 Nov;87(5):1684-96 [10562610.001]
  • [Cites] Proteins. 2001 May 1;43(2):175-85 [11276087.001]
  • [Cites] Trends Endocrinol Metab. 2001 May-Jun;12(4):169-73 [11295573.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Oct;281(4):E794-802 [11551857.001]
  • [Cites] J Neurosci Res. 2001 Dec 1;66(5):824-38 [11746408.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):47-95 [11773609.001]
  • [Cites] Biochem Soc Trans. 2002 Apr;30(2):258-64 [12023861.001]
  • [Cites] AIDS. 2002 Jul 5;16(10):1341-9 [12131210.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 25;304(1):130-5 [12705896.001]
  • [Cites] Neurochem Int. 2003 Sep-Oct;43(4-5):331-8 [12742077.001]
  • [Cites] Brain Res Dev Brain Res. 2003 Jun 12;143(1):33-46 [12763579.001]
  • [Cites] J Physiol. 2004 Jan 15;554(Pt 2):571-8 [14608005.001]
  • [Cites] J Physiol. 2004 Jul 1;558(Pt 1):5-30 [15131240.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Enzyme. 1972;13(4):170-6 [4650384.001]
  • [Cites] Humangenetik. 1975 Jul 23;28(3):239-43 [1150282.001]
  • [Cites] Dev Neurosci. 1998;20(4-5):291-9 [9778565.001]
  • [Cites] Comp Biochem Physiol B Biochem Mol Biol. 1998 May;120(1):89-107 [9787780.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1129-34 [9927705.001]
  • [Cites] J Neurochem. 1999 Mar;72(3):980-7 [10037469.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1999 Jul 29;354(1387):1155-63 [10466143.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Nov;24(11):1241-8 [15545919.001]
  • [Cites] J Neurosci Res. 2005 Jan 1-15;79(1-2):106-13 [15558751.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3159-65 [15548528.001]
  • [Cites] Anal Biochem. 2005 May 1;340(1):41-51 [15802128.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13560-7 [15653680.001]
  • [Cites] Electrophoresis. 2005 Aug;26(15):2892-7 [16078188.001]
  • [Cites] J Biochem Biophys Methods. 2005 Sep 30;64(3):189-99 [16154636.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16448-53 [16260743.001]
  • [Cites] Am J Surg. 1996 Feb;171(2):221-6 [8619454.001]
  • [Cites] J Biol Chem. 1996 Feb 16;271(7):3846-55 [8632003.001]
  • [Cites] J Cereb Blood Flow Metab. 1996 Nov;16(6):1079-89 [8898679.001]
  • [Cites] J Neurochem. 1997 Oct;69(4):1484-90 [9326277.001]
  • [Cites] Biochim Biophys Acta. 1998 Apr 1;1397(1):102-17 [9545551.001]
  • (PMID = 18253497.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitochondrial Proteins; 33X04XA5AT / Lactic Acid; 8L70Q75FXE / Adenosine Triphosphate; EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Other-IDs] NLM/ PMC2212712
  •  go-up   go-down


73. Kabacińska A, Dabrowska A, Tarnowska C, Cyryłowski L: [Diagnostic problems of rare cerebellopontine angle tumors]. Otolaryngol Pol; 2007;61(2):184-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astrocytoma (neuroepithelial tumor) determine about 25% all the cerebroma but their original location in cerebellopontine angle is seldom.
  • The most important in case of this diagnosis is both that this tumors can infiltrate of the brain tissues and the fact that they can transformate toward the anaplastic astrocytoma or glioblastoma multiforme (very malignant tumors).
  • MATERIAL AND METHODS: [corrected] A rare case of astrocytoma presenting as a cerebellopontine angle tumor is discussed.
  • The special characteristics of this tumor and unusual clinical course are disscused.
  • CONCLUSION: The early diagnosis of the astrocytoma increases the patient's chance on convalescence and limits extension of the operation, and consequently of the neurological complication.
  • [MeSH-major] Astrocytoma / radiography. Astrocytoma / surgery. Cerebellar Neoplasms / radiography. Cerebellar Neoplasms / surgery. Cerebellopontine Angle / radiography. Cerebellopontine Angle / surgery. Facial Nerve Diseases / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17668807.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


74. Hagemann C, Gloger J, Anacker J, Said HM, Gerngras S, Kühnel S, Meyer C, Rapp UR, Kämmerer U, Vordermark D, Flentje M, Roosen K, Vince GH: RAF expression in human astrocytic tumors. Int J Mol Med; 2009 Jan;23(1):17-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RAF expression in human astrocytic tumors.
  • Only for A-RAF no link to tumorigenesis has been published so far.
  • Malignant gliomas are the most prevalent primary brain tumors of adults.
  • Although a role of the mitogenic Ras-RAF-MEK-ERK signalling cascade in brain tumor development is well established, there are only few reports available addressing alterations in RAF sequence or protein expression and function in human gliomas.
  • We analysed the mutational status of A-RAF and B-RAF in human glioblastomas (GBM) by sequencing.
  • Then we checked for RAF gene amplification by dot blot hybridization and examined RAF mRNA and protein expression patterns in human astrocytic gliomas of WHO grade II (LGA) and IV (GBM) by semiquantitative RT-PCR and Western blotting, respectively.
  • Finally, we performed functional assays to address a putative function of A-RAF in glioma cell proliferation and migration.
  • A-raf gene amplification was more often detected and overexpression of all three RAF proteins on mRNA and protein level was regularly found in human malignant gliomas.
  • Since neither A-RAF, nor C-RAF expression had any influence on proliferation and migration of GBM cells, putative functions of C-RAF in angiogenesis and of A-RAF in regulation of metabolism are discussed.
  • [MeSH-major] Astrocytoma / genetics. Glioblastoma / genetics. Proto-Oncogene Proteins A-raf / genetics. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins c-raf / genetics
  • [MeSH-minor] Cell Line, Tumor. Cell Movement. Cell Proliferation. Gene Expression Regulation. Humans. Mutant Proteins / genetics. Prognosis. RNA, Messenger / genetics. Sequence Analysis, DNA

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082503.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Mutant Proteins; 0 / RNA, Messenger; EC 2.7.11.1 / Proto-Oncogene Proteins A-raf; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf
  •  go-up   go-down


75. Ahmad Z, Rauf F, Azad NS, Ahsan A: Subependymal giant cell astrocytoma. J Pak Med Assoc; 2006 Oct;56(10):463-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subependymal giant cell astrocytoma.
  • Subependymal giant cell astrocytomas (SEGAs) are slowly growing tumours corresponding to WHO grade I.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144395.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


76. Yen CP, Sheehan J, Steiner M, Patterson G, Steiner L: Gamma knife surgery for focal brainstem gliomas. J Neurosurg; 2007 Jan;106(1):8-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife surgery for focal brainstem gliomas.
  • OBJECT: Focal tumors, a distinct subgroup of which is composed of brainstem gliomas, may have an indolent clinical course.
  • In the present study the authors assess clinical and imaging results in 20 patients who harbored focal brainstem gliomas treated with GKS between 1990 and 2001.
  • The mean tumor volume at the time of GKS was 2.5 cm3.
  • In 10 cases a tumor specimen was obtained either by open surgery or stereotactic biopsy, securing the diagnosis of pilocytic astrocytoma in five patients and nonpilocytic astrocytoma in five others.
  • Patients were followed up for a mean of 78.0 months.
  • Another patient whose tumor disappeared 3 years following GKS died of stroke 8 years postoperatively.
  • Tumor progression occurred in four patients; of these four, one patient developed hydrocephalus requiring a ventriculoperitoneal shunt, two showed neurological deterioration, and one 4-year-old boy died of tumor progression.
  • CONCLUSIONS: Gamma Knife surgery may be an effective primary treatment or adjunct to open surgery for focal brainstem gliomas.
  • [MeSH-major] Brain Stem Neoplasms / surgery. Glioma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome. Tumor Burden

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2007 Sep;107(3):708; author reply 708-9 [17886574.001]
  • [CommentIn] J Neurosurg. 2007 Jan;106(1):6-7 [17262931.001]
  • (PMID = 17236482.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Mezer E, Nischal KK, Nahjawan N, MacKeen LD, Buncic JR: Hemifacial spasm as the initial manifestation of childhood cerebellar astrocytoma. J AAPOS; 2006 Oct;10(5):489-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemifacial spasm as the initial manifestation of childhood cerebellar astrocytoma.

  • Genetic Alliance. consumer health - Cerebellar Astrocytoma, Childhood.
  • Genetic Alliance. consumer health - Hemifacial Spasm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17070492.001).
  • [ISSN] 1091-8531
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Hong X, Nelson KK, deCarvalho AC, Kalkanis SN: Heparanase expression of glioma in human and animal models. J Neurosurg; 2010 Aug;113(2):261-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heparanase expression of glioma in human and animal models.
  • OBJECT: Mammalian heparanase has been shown to function in tumor progression, invasion, and angiogenesis.
  • However, heparanase expression in gliomas has not been well analyzed.
  • To clarify its expression in gliomas, human glioma tissues and glioma animal models were investigated.
  • METHODS: The expression of heparanase mRNA was determined in 33 resected human glioma tissues by semiquantitative real-time polymerase chain reaction.
  • Heparanase expression in murine astrocytoma and human primary neurosphere animal models was examined using IHC.
  • RESULTS: The authors found that heparanase mRNA is greatly increased in gliomas including oligodendroglioma (9 samples), anaplastic astrocytoma (11 samples), and GBM (13 samples) as compared with healthy brain mRNA (3 samples).
  • Note, however, that no significant difference was observed among the 3 tumor groups.
  • Increased heparanase expression was also found in tumor tissues on Western blotting.
  • Heparanase-expressing cells, including GBM tumor cells and neovessel endothelial cells, exhibited decreased expression of CD44, a cell adhesion molecule on the cell membrane that is important for regulating tumor invasion.
  • In addition, heparanase-expressing tumor cells showed an elevated density of the cell proliferation marker Ki 67, as compared with its density in non-heparanase-expressing tumor cells, suggesting that heparanase expression is correlated with enhanced tumor proliferation.
  • Two animal glioma models were tested for heparanase expression.
  • Both murine astrocytoma cells (Ast11.9-2) and cultured primary human GBM neurospheres expressed heparanase when grown in animal brain tissue.
  • CONCLUSIONS: Glioma tissues contain increased levels of heparanase.
  • Multiple cell types contribute to the expression of heparanase, including neovessel endothelial cells, tumor cells, and infiltrated neutrophils.
  • [MeSH-minor] Animals. Antigens, CD44 / genetics. Antigens, CD44 / metabolism. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / physiopathology. Blotting, Western. Disease Models, Animal. Endothelial Cells / physiology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Mice. Mice, Inbred C57BL. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Oligodendroglioma / physiopathology. RNA, Messenger / metabolism. Rats. Rats, Nude. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835469.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44 protein, human; 0 / RNA, Messenger; EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


79. Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z: Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol; 2009 Apr;30(4):681-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease?
  • BACKGROUND AND PURPOSE: Current classification and grading of primary brain tumors has significant limitations.
  • Our aim was to determine whether the relative cerebral volume (rCBV) measurements in gliomas may serve as an adjunct to histopathologic grading, with a hypothesis that rCBV values are more accurate in predicting 1-year survival and recurrence.
  • MATERIALS AND METHODS: Thirty-four patients with gliomas (WHO grade I-IV, 27 astrocytomas, 7 tumors with oligodendroglial components) underwent contrast-enhanced MR rCBV measurements before treatment.
  • The rCBV(mean) and rCBV(max) in the astrocytomas were 3.5 +/- 2.9 and 3.7 +/- 2.7.
  • The combined CBV-WHO grade classification enhanced the predictive value for recurrence/progression (P < .0001).
  • CONCLUSIONS: rCBV values in astrocytomas but not tumors with oligodendroglial components are predictive for recurrence and 1-year survival and may be more accurate than histopathologic grading.
  • [MeSH-major] Astrocytoma / pathology. Blood Volume. Brain Neoplasms / pathology. Cerebrovascular Circulation. Magnetic Resonance Imaging / methods. Oligodendroglioma / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179427.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Llaguno SA, Chen J, Kwon CH, Parada LF: Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma. Cold Spring Harb Symp Quant Biol; 2008;73:421-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neural and cancer stem cells in tumor suppressor mouse models of malignant astrocytoma.
  • Malignant astrocytomas are highly invasive brain tumors that portend poor prognosis and dismal survival.
  • We previously reported tumor suppressor mouse models based on conditional inactivation of human astrocytoma-relevant genes p53, Nf1, and Pten.
  • These mice develop, with full penetrance, varying grades of astrocytic malignancy that recapitulate the human condition histologically and molecularly.
  • Our studies indicate a central role for neural stem cells and stem-cell-like cancer cells in tumor initiation and progression.
  • These mouse models thus represent powerful tools for investigating various aspects of tumor development that otherwise cannot be explored in humans.
  • Further studies will provide a better understanding of the biology of these tumors and will hopefully pave the way for more effective therapeutic approaches for these devastating diseases.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology. Neurons / pathology
  • [MeSH-minor] Animals. Disease Models, Animal. Genes, Tumor Suppressor. Humans. Mice. Models, Neurological. Mutation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19022744.001).
  • [ISSN] 1943-4456
  • [Journal-full-title] Cold Spring Harbor symposia on quantitative biology
  • [ISO-abbreviation] Cold Spring Harb. Symp. Quant. Biol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / P50NS05260602
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


81. Subbiah V, Huff V, Wolff JE, Ketonen L, Lang FF Jr, Stewart J, Langford L, Herzog CE: Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome. Pediatr Blood Cancer; 2009 Dec 15;53(7):1349-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome.
  • Frasier syndrome is characterized by a 46 XY disorder of sex development, nephropathy, and increased risk for gonadoblastoma due to Wilms tumor 1(WT1) mutation in the donor splice site of intron-9, resulting in the splice form +KTS.
  • We present the clinical, radiological, and genetic (WT1 mutation analysis) of a 46 XY phenotypic female with Frasier syndrome with bilateral gonadoblastoma with dysgerminoma who developed pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Dysgerminoma / genetics. Frasier Syndrome / genetics. Genes, Wilms Tumor. Gonadoblastoma / genetics. Hypothalamic Neoplasms / genetics. Neoplastic Syndromes, Hereditary / genetics. Point Mutation. RNA Splice Sites / genetics


82. El-Rayes BF, Norton CS, Sakr W, Maciorowski Z, Smith D, Pietraszkiewicz H, Del Mar Alonso M, Ensley JF: Cellular DNA content parameters as prognostic indicators in human astrocytomas. J Neurooncol; 2005 Jan;71(2):85-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular DNA content parameters as prognostic indicators in human astrocytomas.
  • OBJECTIVE: Clinical parameters such as grade, size and/or location of the tumor are good predictors of outcome in patients with astrocytoma.
  • METHODS: Following optimization and validation of methodology for evaluating cellular DNA content parameters (CDCP), tumor DNA ploidy and percent S phase fraction (SPF) were determined from 64 patients using formalin fixed, paraffin embedded specimens (mean coefficient of variation=4.94) obtained over a 10-year period.
  • CONCLUSION: DNA content parameters may correlate with the natural history and treatment outcome of newly diagnosed untreated patients with astrocytomas.
  • [MeSH-major] Astrocytoma / metabolism. Central Nervous System Neoplasms / metabolism. DNA, Neoplasm / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Jul 1;60(1):59-65 [2438028.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cytometry. 1985 Jul;6(4):327-33 [4017799.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):672-83 [10440696.001]
  • [Cites] Clin Neuropathol. 1986 Jul-Aug;5(4):157-75 [3757347.001]
  • [Cites] Neuropathol Appl Neurobiol. 1989 Jul-Aug;15(4):331-8 [2779735.001]
  • [Cites] J Neurosurg. 1980 Aug;53(2):198-204 [7431058.001]
  • [Cites] Neurosurg Rev. 1988;11(2):177-87 [3244416.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):663-7 [2071227.001]
  • [Cites] Am J Clin Pathol. 1988 Sep;90(3):289-93 [2843034.001]
  • [Cites] J Neurosurg. 1994 May;80(5):877-83 [8169628.001]
  • [Cites] Cytometry. 1988 Jul;9(4):380-6 [2841078.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]
  • [Cites] Pol J Pathol. 1997;48(1):31-6 [9200958.001]
  • [Cites] Cytometry. 1987 Sep;8(5):479-87 [2444398.001]
  • [Cites] Cell Tissue Kinet. 1982 May;15(3):235-49 [7083295.001]
  • [Cites] Folia Histochem Cytobiol. 2000;38(4):175-80 [11185722.001]
  • [Cites] J Neurosurg. 1978 Jul;49(1):13-21 [207834.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 May;16(5):1001-12 [7639120.001]
  • [Cites] Acta Neuropathol. 1979 Apr 12;46(1-2):39-44 [222110.001]
  • [Cites] J Neurosurg. 1994 Jan;80(1):85-9 [8271026.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1385-90 [10022821.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):153-8 [9739018.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):77-89 [8055485.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Neurosurgery. 1994 Jul;35(1):119-25; discussion 125-6 [7936132.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):920-7 [8039120.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):711-28 [3001488.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):379-84 [2536805.001]
  • [Cites] Cytometry. 1983 Mar;3(5):328-31 [6839881.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):113-7 [8548733.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):7-17 [9049858.001]
  • [Cites] J Neuropathol Exp Neurol. 1990 Jan;49(1):71-8 [2153761.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):37-45 [8865001.001]
  • [Cites] Am J Clin Pathol. 1988 May;89(5):640-4 [2895977.001]
  • [Cites] Cytometry. 1987 Sep;8(5):488-93 [3665673.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):538-46 [1319820.001]
  • (PMID = 15690121.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 40498-01A1; United States / NCI NIH HHS / CA / P30CA22453
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm
  •  go-up   go-down


83. Kumar R, Kamdar D, Madden L, Hills C, Crooks D, O'Brien D, Greenman J: Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep; 2006 Jun;15(6):1513-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients.
  • Patients were divided into various groups depending on their histological diagnosis: meningioma (n=11), anaplastic astrocytoma (n=4) and glioblastoma multiforme (GBM; n=46).
  • Significant reduction in serum IL-12 was seen in all groups as compared with the controls: meningioma, p=0.03; anaplastic astrocytoma, p<0.001; and GBM, p<0.001.
  • Conversely, serum IL-10 was significantly increased in anaplastic astrocytoma, p=0.02, and GBM, p=0.03.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-10 / blood. Interleukin-12 / blood. Meningioma / immunology. Th1 Cells / immunology. Th2 Cells / immunology


84. Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, Sommer C, Kaina B: MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer; 2010 Nov 1;127(9):2106-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma.
  • The DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT) is a key player in tumor cell resistance.
  • However, it is unclear whether MGMT promoter methylation correlates with MGMT activity and whether MGMT promoter methylation of the pretreatment tumor predicts the MGMT status of recurrences.
  • To address these questions, we determined MGMT activity promoter methylation and immunoreactivity in pretreatment and recurrent glioblastomas (GB, WHO Grade IV), and in astrocytomas (WHO Grade III).
  • For astrocytomas, promoter-methylated samples displayed 0-28 fmol/mg and, nonmethylated samples, 23-107 fmol/mg.
  • Therefore, classification of hemimethylated tumors remains questionable.
  • Although individual exceptions were found, the data show an overall correlation between promoter methylation and lack/low MGMT activity in GB and astrocytomas.
  • [MeSH-major] Astrocytoma / enzymology. Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. DNA Methylation. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. Glioblastoma / enzymology. Glioblastoma / genetics. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Immunohistochemistry. Recurrence

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20131314.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


85. Reis F, Faria AV, Zanardi VA, Menezes JR, Cendes F, Queiroz LS: Neuroimaging in pineal tumors. J Neuroimaging; 2006 Jan;16(1):52-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: The authors report radiological findings in 11 tumors in the pineal region, which were histologically diagnosed as germinomas, pineocytomas pineoblastomas, ependymomas, teratomas, and astrocytomas.
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / diagnosis. Child. Diagnosis, Differential. Ependymoma / diagnosis. Female. Germinoma / diagnosis. Humans. Magnetic Resonance Imaging. Male. Neuroblastoma / diagnosis. Prognosis. Teratoma / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483277.001).
  • [ISSN] 1051-2284
  • [Journal-full-title] Journal of neuroimaging : official journal of the American Society of Neuroimaging
  • [ISO-abbreviation] J Neuroimaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Su YW, Chang MC, Chiang MF, Hsieh RK: Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol; 2005 Feb;71(3):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.
  • In patients with recurrent malignant glioma, treatment-related myelodysplastic syndrome (t-MDS) and acute leukemia are rare adverse effects because the median survival after relapse is limited.
  • We report a 44-year-old woman with t-MDS (refractory anemia with excess blasts) following treatment of recurrent anaplastic astrocytoma with temozolomide (TMZ).
  • The disease rapidly evolved into acute leukemia within 1 month after the onset of MDS, and the patient died 1 month later during induction chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Leukemia / chemically induced. Myelodysplastic Syndromes / chemically induced. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Chromosomes, Human, Pair 11. Fatal Outcome. Female. Gene Deletion. Humans


87. Callovini GM: Is it appropriate to redefine the indication for stereotactic brain biopsy in the MRI Era? Correlation with final histological diagnosis in supratentorial gliomas. Minim Invasive Neurosurg; 2008 Apr;51(2):109-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is it appropriate to redefine the indication for stereotactic brain biopsy in the MRI Era? Correlation with final histological diagnosis in supratentorial gliomas.
  • On the basis of the MRI findings the patients were divided into two groups: high-grade (n=107) and low-grade (n=67) gliomas.
  • In the group of high-grade gliomas (HGG) there was diagnostic coincidence in 87% of cases, reaching 100% in lesions of the corpus callosum.
  • In the group of low-grade gliomas (LGG) there was diagnostic coincidence in 63% (42 cases), whereas there was discordance in 30%: 10 cases were upgraded to anaplastic astrocytoma, and in 10 cases no tumors were observed at all.
  • Today, the indications for biopsy in lesions mimicking high-grade gliomas are mainly linked to the site of the tumor, coexisting differential diagnoses or more than one treatment option.
  • On the contrary, in lesions where MRI findings indicate low-grade gliomas, grading is crucial also in order to avoid treatment inappropriate in non-neoplastic lesions.
  • [MeSH-major] Astrocytoma / pathology. Brain / pathology. Glioma / pathology. Magnetic Resonance Imaging / standards. Neoplasm Recurrence, Local / pathology. Stereotaxic Techniques / standards. Supratentorial Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18401825.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. McGirt MJ, Chaichana KL, Atiba A, Attenello F, Woodworth GF, Jallo GI: Neurological outcome after resection of intramedullary spinal cord tumors in children. Childs Nerv Syst; 2008 Jan;24(1):93-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathology revealed astrocytoma in 12 cases (three pilocytic, four grade II, three grade III, two GBM), gangliogliomas in two, ependymoma in one, and gliosis in one case.
  • Preoperative steroid use (odds ratio, OR [95% confidence interval, CI] = 18.0 [1.24-260.1], p = 0.03) and cystic tumor (OR [95%CI] = 18.0 [1.24-260.1], p = 0.03) predicted neurological improvement after surgery.
  • [MeSH-minor] Adolescent. Astrocytoma / complications. Astrocytoma / surgery. Cervical Vertebrae / pathology. Child. Child, Preschool. Ependymoma / complications. Ependymoma / surgery. Female. Ganglioglioma / complications. Ganglioglioma / surgery. Humans. Magnetic Resonance Imaging / methods. Male. Prospective Studies. Quality of Life. Thoracic Vertebrae / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1989 Sep;39(9):1255-7 [2771077.001]
  • [Cites] J Neurosurg. 1981 Jun;54(6):829-32 [7241192.001]
  • [Cites] Neurosurgery. 1988 Jun;22(6 Pt 1):1005-7 [3419560.001]
  • [Cites] J Neurosurg. 2000 Oct;93(2 Suppl):183-93 [11012047.001]
  • [Cites] Neurosurg Clin N Am. 1990 Jul;1(3):609-30 [2136161.001]
  • [Cites] Neurosurgery. 1989 Dec;25(6):855-9 [2601814.001]
  • [Cites] J Neurooncol. 2001 May;53(1):61-6 [11678433.001]
  • [Cites] Spinal Cord. 2005 Jan;43(1):34-41 [15326473.001]
  • [Cites] J Neurosurg. 1993 Aug;79(2):204-9 [8331401.001]
  • [Cites] Neurosurg Focus. 2006 Feb 15;20(2):E2 [16512653.001]
  • [Cites] J Neurosurg. 1992 Sep;77(3):355-9 [1506881.001]
  • [Cites] Curr Treat Options Neurol. 2003 May;5(3):207-212 [12670409.001]
  • [Cites] J Neurosurg Spine. 2005 Mar;2(3):249-55 [15796348.001]
  • [Cites] J Neurosurg. 1981 Mar;54(3):323-30 [7463133.001]
  • [Cites] Neurosurgery. 1999 Feb;44(2):264-9 [9932879.001]
  • [Cites] Spine (Phila Pa 1976). 2005 Nov 1;30(21):2362-7; discussion 2368 [16261109.001]
  • [Cites] Spine (Phila Pa 1976). 1997 Feb 15;22(4):442-51 [9055374.001]
  • [Cites] J Neurosurg. 1989 Jun;70(6):920-5 [2715820.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1976 Mar;39(3):290-6 [932744.001]
  • [Cites] Neurosurg Clin N Am. 1992 Oct;3(4):931-45 [1392585.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1036-43 [8929492.001]
  • [Cites] Neurosurgery. 1994 Jul;35(1):69-74; discussion 74-6 [7936155.001]
  • [Cites] Childs Nerv Syst. 2003 Sep;19(9):641-9 [12908118.001]
  • [Cites] Pediatr Neurosurg. 2001 Dec;35(6):318-24 [11786700.001]
  • [Cites] J Neurosurg. 1992 Jul;77(1):90-5 [1607978.001]
  • [Cites] J Neurooncol. 2004 May;68(1):71-7 [15174523.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1124-8 [11846906.001]
  • (PMID = 17665203.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA: Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol; 2006 Aug 1;24(22):3644-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
  • PURPOSE: TM-601 binds to malignant brain tumor cells with high affinity and does not seem to bind to normal brain tissue.
  • Preclinical studies suggest that iodine-131 (131I) -TM-601 may be an effective targeted therapy for the treatment of glioma.
  • We evaluated the safety, biodistribution, and dosimetry of intracavitary-administered 131I-TM-601 in patients with recurrent glioma.
  • PATIENTS AND METHODS: Eighteen adult patients (17 with glioblastoma multiforme and one with anaplastic astrocytoma) with histologically documented recurrent glioma and a Karnofsky performance status of > or = 60% who were eligible for cytoreductive craniotomy were enrolled.
  • An intracavitary catheter with subcutaneous reservoir was placed in the tumor cavity during surgery.
  • 131I-TM-601 bound to the tumor periphery and demonstrated long-term retention at the tumor with minimal uptake in any other organ system.
  • At day 180, four patients had radiographic stable disease, and one had a partial response.
  • Two of these patients further improved and were without evidence of disease for more than 30 months.
  • [MeSH-major] Brachytherapy. Brain Neoplasms / radiotherapy. Glioma / radiography. Iodine Radioisotopes / administration & dosage. Iodine Radioisotopes / adverse effects. Scorpion Venoms / administration & dosage. Scorpion Venoms / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Karnofsky Performance Status. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Radiometry. Radiopharmaceuticals / administration & dosage. Radiopharmaceuticals / adverse effects. Radiotherapy Dosage. Survival Analysis. Time Factors. Tomography, Emission-Computed, Single-Photon. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16877732.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorotoxin; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Scorpion Venoms
  •  go-up   go-down


90. Ng WH, Lim T: Targeting regions with highest lipid content on MR spectroscopy may improve diagnostic yield in stereotactic biopsy. J Clin Neurosci; 2008 May;15(5):502-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are heterogeneous brain tumors and prognosis and treatment are dependent on the highest histological grade present.
  • MRS studies in brain tumors have found increased levels of choline-containing compounds (Cho) and decreased levels of N-acetylaspartate (NAA), creatine (Cr) and phosphocreatine (PCr) which are all associated with increased grade of glioma.
  • We propose the use of MRS-guided stereotactic biopsy of astrocytomas to increase diagnostic yield and reduce the sampling error rate.
  • MRS was performed on two patients undergoing stereotactic biopsy for suspected astrocytoma.
  • Histological grade was found to be different in one case: the region with a high Lip/Cr and Cho/NAA ratios showed glioblastoma, whereas the region with high Cho/NAA but low Lip/Cr ratios showed anaplastic astrocytoma.
  • The second patient had high Cho/NAA ratio but low Lip/Cr ratio in both targets and the histology revealed anaplastic astrocytoma in both samples.
  • MRS is a useful biomedical imaging tool for diagnosing and grading astrocytomas.
  • [MeSH-major] Brain Neoplasms / diagnosis. Glioma / diagnosis. Lipids / analysis. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334298.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Lipids
  •  go-up   go-down


91. Chou CH, Lieu AS, Wu CH, Chang LK, Loh JK, Lin RC, Chen WJ, Liao HD, Fu WS, Chang CS, Lin CC, Hsu CM, Chio CC, Howng SL, Hong YR: Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors. Oncol Rep; 2010 Nov;24(5):1225-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our results also indicated that Snail and E-cadherin showed opposing expression in malignant tumors (high grade astrocytoma and metastasis).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878114.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / snail family transcription factors
  •  go-up   go-down


92. Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, Nakamura R, Iseki H, Hori T, Takakura K: Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg; 2008 Oct;51(5):275-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate?
  • The objective of the present study was an evaluation of the incidence and risk factors for erroneous histopathological diagnosis of low-grade glioma after stereotactic biopsy.
  • Twenty-eight tumors diagnosed as low-grade glioma after stereotactic biopsy and surgically resected thereafter were analyzed.
  • There were 13 astrocytomas, 7 oligodendrogliomas, and 8 mixed gliomas.
  • Complete diagnostic agreement in tumor typing and grading after stereotactic biopsy and surgical resection was attained in 10 cases (36%).
  • Agreement in tumor typing was marked in 16 cases (57%).
  • Erroneous typing was more frequent in tumors with an MIB-1 index of less than 3% (P = 0.0629) and mixed gliomas (P = 0.0801).
  • Overgrading of WHO grade I tumors was marked in 3 cases (11%) and undergrading of WHO grade III gliomas in 8 cases (28%).
  • Tumor undergrading was more frequent in cases with an MIB-1 index of more than 3% (P = 0.0045).
  • In conclusion, the histopathological diagnosis of low-grade glioma established after stereotactic biopsy is associated with a substantial risk of inaccuracy.
  • Tumors with low proliferative activity and mixed gliomas are especially susceptible for erroneous tumor typing.
  • Undergrading of high-grade gliomas may be suspected if the MIB-1 index in the tumor specimen constitutes more, than 3%.
  • [MeSH-major] Brain Neoplasms / pathology. Diagnostic Errors / statistics & numerical data. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Biopsy / statistics & numerical data. Brain / pathology. Brain / surgery. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Mitotic Index. Neurosurgical Procedures. Observer Variation. Oligodendroglioma / pathology. Predictive Value of Tests. Reproducibility of Results. Stereotaxic Techniques / statistics & numerical data. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855292.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


93. Kinjo S, Hirato J, Nakazato Y: Low grade diffuse gliomas: shared cellular composition and morphometric differences. Neuropathology; 2008 Oct;28(5):455-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade diffuse gliomas: shared cellular composition and morphometric differences.
  • Low grade diffuse gliomas arising in the brain are challenging to treat because of their ability to infiltrate adjacent tissue.
  • We attempted to clarify the cellular composition and histopathological features of low grade gliomas by utilizing morphometric and immunohistochemical analyses.
  • Seventy-eight cases of low grade gliomas were examined including 21 diffuse astrocytomas (DA), 36 oligodendrogliomas (OL), and 21 oligoastrocytomas (OA), based on the WHO classification system.
  • Double immunostaining revealed that expression of Olig2 and GFAP, and Olig2 and nestin was mutually exclusive in most glioma cells.
  • We conclude that each glioma include cells expressing GFAP, cells expressing nestin, and cells expressing Olig2 in a characteristic proportion for each tumor type.
  • We suggest that diffuse gliomas share cellular compositions in different ratios and that they can be distinguished by morphometrical analysis.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Glioma / metabolism. Glioma / pathology
  • [MeSH-minor] Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Intermediate Filament Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. Nestin. Tumor Suppressor Protein p53 / biosynthesis